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Abstract 
Potentially inappropriate medications (PIMs) are prescribed most often to elderly patients and 
can cause serious adverse effects. Older adults tend to use multiple medications, and age-related 
physiological changes can make some medications inappropriate. The aims of this study are to 
determine the prevalence of PIMs use for older patients admitted to rural hospitals; to identify 
the most frequently prescribed PIMs in this population; to compare the number of PIMs 
identified using two tools, STOPP criteria and Beers’ criteria; and to identify the total number of 
PIMs identified when using both sets of criteria. Secondly, this study explores the factors 
associated with PIMs use in this group. These objectives were examined through an 
observational study design involving patients aged 65 years and above at rural hospitals. Of the 
178 patients enrolled, the median age was 80 and 93 participants (52.2%) were female. The 
collected data included demographic patient information, medical histories and current 
diagnoses, number and type of PIMs, and total number of prescribed medications. Using Beers’ 
criteria, the prevalence of taking at least one PIM was 62.92% among the population, with 112 
older adults using 202 PIMs. Using the STOPP criteria, the prevalence of receiving at least one 
PIM was 69.10%, with 123 patients using 240 PIMs. When both sets of criteria were applied, the 
proportion using one or more PIMs increased to 73.03%, representing 130 patients using 330 
PIMs. Bivariate logistic regression models showed no predictable associations between PIM use 
and gender, number of illnesses, or age when using both the STOPP and combined criteria 
models. In contrast, a positive association was found between PIM use and the number of 
medications, the presence of neurological or urogenital diseases, and age using Beers’ criteria. 
This study provided insight into the higher prevalence of PIMs in rural healthcare settings. The 
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higher prevalence and number of PIMs under STOPP criteria compared to the Beers criteria were 
due to differences in their features, while these variances were eliminated when both criteria 
were concurrently applied. The continued use of PIMs among older patients is a crucial issue that 
requires further research to discover the underlying reasons of continued prescription of PIMs 
particularly in rural regions, and to determine an ideal approach that prevents PIM-related 
problems. 
 
Keywords: Potentially inappropriate medications, STOPP criteria, Beers’ criteria, older adults, 
rural hospitals 
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Chapter 1: Introduction 
1.1 Definition 
The optimization of prescribed medications for the elderly is a global concern for health 
care providers and researchers who attempt to improve the safety of medications. One of the foci 
of pharmaceutical research is the standardization of the selection of medications to be prescribed 
for this population. Appropriate medication use for older adults is a major challenge encountered 
by prescribers, even with medications not considered contraindicated. Some medications, if 
prescribed under certain conditions, will probably harm one’s health. So, a consensus of health 
care professionals, researchers, and specialists in geriatric care are working to eliminate this 
problem that may contribute to worsening of complex diseases in older adults. Particular 
medications administered under specific conditions have been categorized and identified as 
potentially inappropriate medications (PIMs). A PIM is defined as a medication that can create 
serious problems when the risks of adverse drug reactions outweigh the benefits of the 
medication compared with alternative treatments, especially if an alternative treatment is 
available and safer for the same condition (Beers et al., 1991; Gallagher & O’Mahony, 2008; 
Keith et al., 2013).The prescription of PIMs has negative clinical and economic outcomes, 
especially among the elderly. PIMs are widely prevalent around the world, and the estimated 
percentage of the prevalence of PIMs is approximately 6% to 41% (Kaur et al., 2009). 
 2 
  
1.2 Reasons to consider a medication as a PIM 
After a comprehensive review of literature, it is found that there are two main factors that 
cause different reactions to medications and contribute to worsening elders’ conditions, and that 
make those medications inappropriate. 
1.2.1 Aging and physiological changes 
Many medications are considered inappropriate for older patients due to age-related 
physiological changes. Despite inter-individual variants among elders, generally the functions 
and compositions of body systems are changed from youth. These changes continue with 
advancing age, often leading to adverse effects from medications not seen in younger patients, 
even among safer drugs. Age-related physiological changes encompass and affect both 
pharmacokinetic and pharmacodynamic processes as detailed in the following section. 
1.2.1.1 Age-related physiological change: Pharmacokinetics Pharmacokinetic processes consist 
of drug absorption, distribution, metabolism, and excretion. 
1.2.1.1.1 Drug absorption. Age-related physiological changes include reductions in the surface 
of the intestinal epithelium, gut motor function, splanchnic blood flow, and possibly stomach 
acid. However, the bioavailability of most drugs is not affected by these changes because most 
drugs are absorbed via passive diffusion. 
A few drugs are affected by a decreased rate of absorption due to aging, such as indomethacin, 
prazosin, digoxin (Turnheim, 2003). Some drugs require an acidic environment for absorption 
and any changes in the gastric environment due to aging will affect the bioavailability of some 
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compounds that require an acidic environment in order to be ionized, such as ketoconazole, 
ampicillin esters, and iron compounds (McLean & LeCouteur, 2004). Supplements such as 
calcium, iron, and vitamins are absorbed by the intestinal epithelium through specific carrier-
mediated transport mechanisms. Seniors may experience a reduction in absorbability for these 
specific transport mechanisms, affecting the bioavailability of those nutrients (Turnheim, 2003; 
Mangoni & Jackson, 2004). 
The normal aging process leads to degeneration of the epidermis and dermis. Tissue blood 
perfusion, specifically, and general barrier functions of the skin are reduced. The transdermal 
drug absorption rate may therefore decrease with age (Turnheim, 2003). However, drug 
absorption as a function of aging does not decrease to any clinically relevant extent for most 
drugs. 
1.2.1.1.2. Drug distribution. Medication distribution is dependent on many factors that might 
change with aging including blood flow, plasma protein binding, and body composition (DiPiro 
et al., 2014). Aging leads to decreases in body mass, especially skeletal muscle mass. The total 
body water content also declines by 10-15%. For this reason, the distribution volume of 
hydrophilic, or water-soluble, drugs (e.g. aspirin, tubocurarine, edrophonium, famotidine, and 
lithium) decreases. Consequently, the volume of distribution for water-soluble drugs decreases, 
but the serum concentrations increase. Total body fat, on the other hand, increases with age. 
Body fat among females increases by 33-45%, while body fat among males increases by 18-
36%. When the volume of distribution is increased, the plasma half-life of lipid-soluble drugs is 
increased as a result. Examples of lipid-soluble drugs are amiodarone, diazepam, teicoplanin, and 
verapamil (Turnheim, 2003). 
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Drugs in the blood bind to plasma protein, and only the free fraction of drugs is 
pharmacologically active. When plasma albumin levels decrease to a certain level in older 
people, the concentration of α1-glycoprotein (which binds alkaline drugs) increases or 
remains unchanged. When the free (unbound) drug concentration increases, drug elimination 
rises as well. Therefore, these changes in plasma protein binding due to aging are not 
clinically important.  It is noticed that slight decrease in the binding of plasma proteins and 
increase in unbound drugs could be occur in older patients with specific conditions such as 
renal or hepatic dysfunction as well as  malnourishment in older patients with late-stage 
cancers. In fact, it is necessary to emphasize that these changes in protein binding are not due 
to aging but some diseases or conditions lead to small alterations in protein concentration 
(Turnheim, 2003; Mangoni & Jackson, 2003). 
1.2.1.1.3 Drug metabolism: Liver. Hepatic drug metabolism during the aging process is not 
fully understood. The liver structure changes and liver size decreases by approximately 25-
35% in old age. The endoplasmic reticulum is weakened so that hepatic extracellular space 
increases. Moreover, hepatic blood flow decreases by 40%, which subsequently reduces bile 
flow and the synthesis of proteins, lipids, and glucose. In vivo, the metabolic clearance for 
some drugs may decrease by 20-40% or remain unchanged depending on the extraction ratio 
for each drug. Inter-individual variations have a greater effect on metabolic drug processes 
than do aging changes related to drug metabolism (Turnheim, 2003). 
Blood flow and extraction ratio, which determine the level of drug clearance in the liver, are 
important factors in monitoring the toxicity of drugs (Mangoni & Jackson, 2003). The 
extraction ratio is based on the liver’s capacity to metabolize drugs. With advancing age, 
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blood flow may decrease and affect liver clearance. This process mainly affects high 
extraction ratio drugs such as chlormethiazole, dextropropoxyphene, glyceryl nitrate, 
lignocaine, pethidine, and propranolol (Turnheim, 2003). Aging has no effect on phase-II or 
conjugation reactions while aging does affect the action of  the membrane-bound cytochrome 
P450 microsomal cytochrome P450 enzymes (CYP), which are oxidative enzymes and 
regulate the phase-I metabolism. Moreover, some CYP 450 isoforms have decreased activity 
with advanced age, while others remain unchanged (Schwartz & Abernethy, 2009).   
1.2.1.1.4. Drug excretion: Kidney. The physiology and structure of the kidney change with 
age. The number of glomeruli, which is part of the nephron, and renal blood flow decreases 
with advanced age (after age 40). Renal blood flow decreases approximately 1% decrement 
per year due to factors such as increased angiotensin-II and endothelin levels and decreased 
prostaglandin concentrations (Turnheim, 2003). Furthermore, intra-renal vascular changes in 
the kidney (except in the medullary vasculature area, in which there is no change) contribute 
to this decrease in renal blood flow. Kidney mass generally decreases with age (Mangoni & 
Jackson, 2003). The efficiency of renal clearance and the glomerular filtration rate decreases 
in older people. After age 20, the glomerular filtration rate reduces by 25% to50%. This 
decline in glomerular filtration rate can induce drug side effects for drugs that are mainly 
excreted by the kidney (Turnheim, 2003). 
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1.2.1.2 Age-related physiological change: Pharmacodynamics. Pharmacokinetics deals with the 
effects of drug concentration on actions, whereas pharmacodynamics deals with the effects that 
drugs have on the body and how the drugs exert these effects. The changes in pharmacodynamics 
among older people may impact drug receptor numbers, receptor affinity, or homeostatic 
mechanisms (Turnheim, 2003; DiPiro et al., 2014). Most studies examined these alterations in 
the cardiovascular and nervous systems. 
Decreasing receptor response to the substrate or drugs has been observed in the cardiovascular 
system. For example, reduced β-adrenoceptors affinity to agonists is reported in older people. In 
particular, the receptors’ sensitivity in the myocardium to catecholamine is poor. The nervous 
system also changes with age. Between the ages of 20 and 80, brain weight decreases by 20% 
and neuron loss occurs, leading to a change in brain structure. A reduction in the number of 
synapses is also reported. Nervous system changes in compositions and responses, including 
reductions in the number of dopaminergic neurons and dopamine D2 receptors and cholinergic 
neurons and receptors are reported in older individuals. In addition, the central nervous system 
has a higher sensitivity to the action of benzodiazepines in older people than in younger people. 
These changes in the nervous system contribute to adverse drug side effects (Turnheim, 2003). 
1.2.2 Polypharmacy 
Due to age-related increases in pathological conditions, older individuals are more likely to 
consumption of multiple medications (polypharmacy). Polypharmacy is (generally-not everyone 
agrees) defined as the administration of five or more medications (Bregnhoj et al., 2009; 
Bushardt et al., 2008). Despite benefitting many patients, polypharmacy is also the most frequent 
cause of PIM-related problems due to the risk of drug–drug interactions or drug–disease 
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interactions (Pitkala et al., 2012). This was demonstrated by Goldberg and colleagues who found 
that the risk of adverse drug–drug interactions for patients taking two medications is 13%, 38% 
for patients taking four drugs, and 82% for patients taking seven or more medications (Goldberg 
et al., 1996). When polypharmacy is used to treat multiple chronic conditions, even relatively 
safe drugs can interact in dangerous ways. Hospitalized patients who are administered five to 
seven drugs have a 58% higher risk of developing adverse drug events (ADEs) than patients who 
use fewer than five medications and quadruples for patients taking eight or more drugs (Onder et 
al., 2010; Scott et al., 2012). Furthermore, many disabled older adults dependent on others have 
difficulty adhering to a medication treatment plan (Bergqvist et al., 2009). Overall, patients 
taking a larger number of medications are more likely to have PIMs. 
1.3 Consequences of Prescribed PIMs 
1.3.1 Adverse drug reactions 
While the causes of ADEs are well-documented in older adults, the first version of the 
Beers’ criteria drew researchers and caregivers to investigate the association between PIMs and 
ADEs, and this research is ongoing. 
The most common side effects of PIMs are conditions such as orthostatic hypotension, cognitive 
impairment, falls, and fractures. This is exemplified by an American report that showed that 
cognitive deficit results from taking PIMs among patients with mild cognitive impairment 
(Weston et al., 2010). Most hip fractures and admissions in hospitals of older adults result from 
falls, which can be caused by PIMs (Agashivala & Wu, 2009). The risk of falling rises 
meaningfully per use of potentially inappropriate psychotropic medications of the Beers’ criteria 
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in nursing home settings, with an increased risk of approximately 20.5% in patients receiving 
potentially inappropriate psychotropic medications compared to patients receiving other 
psychoactive medications, and this percentage increased to 60.3% when compared to patients not 
receiving any kind of psychoactive medications (Agashivala & Wu, 2009). This finding was 
confirmed in a French evaluation of all inappropriate medications leading to falling, that found 
that use of those medications by older adults increased the risk of falling, especially with long-
acting benzodiazepines, psychotropics, and anticholinergic medications (Berdot et al., 2009). 
Previous research attempts to determine ADEs associated with use of PIMs evaluated the decline 
of the health status in general (Fu et al., 2004). An association between PIMs and serious side 
effects that resulted in a general decline in functionality was identified in two studies conducted 
in Italy. These studies had different results, probably due to variance in the study setting and 
unadjusted potential confounders. The first study shows a strong relation between the use of 
PIMs and physical disability in community-dwelling, frail, older adults (Landi et al., 2007), 
while the second study found no associations between functional disability in older patients and 
use of PIMs in acute medical wards (Corsonello et.al, 2009). Regardless, most ADEs could have 
been prevented and reduced by reviewing and assessing the appropriateness of the medication 
prescribed per older adult (Gurwitz et al., 2003). 
Furthermore, an association exists between increased use of health services and ADEs resulting 
from PIMs, such as increased outpatient visits (Fillenbaum et. al., 2004) and presentation to the 
emergency department (Nixdorff et al., 2008). A recent pilot Canadian study determined that 
65% of patients receiving PIMs lead them to frequent emergency department visits (Wong et al., 
2014). Likewise, an Irish study noted a prevalence of PIMs of about 50% among patients who 
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were older than 70 years and visiting the emergency department due to falls (McMahon et al., 
2014). The greater number of hospitalizations in older adults can be attributed to PIMs. For 
example, a large population-based study in Australia found that the risk of unplanned 
hospitalizations of older adults increased with the number of PIMs consumed (Price et al., 2014). 
A relationship between ADEs and hospital readmissions was determined in a study that found 
that 10–30% of hospital readmissions among older adults are due to drug-related problems 
(Bonnet-Zamponi et al., 2013). Moreover, many of these readmissions to hospital for drug-
related problems could have been prevented (Bero et al., 1991). Thus, ADEs of inappropriate 
prescriptions are common in hospitalized older patients with polypharmacy. 
Finally, there is an association between increasing mortality among older adults and ADEs. Up 
to 18% of inpatient deaths may be attributable to ADEs, with most caused by inappropriate 
prescription medications (Scott et al., 2012; Gallagher et al., 2007). Studies set in nursing homes 
observed that residents who had at least one PIM in the prior year had an increased risk of being 
hospitalized and an increased risk death (Lau et al., 2005 ; Dedhiya et al., 2010). 
1.3.2 Health care expenditures 
PIMs also increase the cost of drug-related problems. While few studies have investigated 
the relationship between PIMs and their expenses for health care systems in particular, Irish 
retrospective studies measured the costs of prescribing PIMs. A first study on the national 
population found that one-third of the study’s older population used at least one PIM, resulting in 
a cost of 9% (€45,631,319) of the total pharmaceutical expenditures in 2007 (Cahir et al., 2010). 
A second study determined the prevalence of PIMs in 2009/2010 in Northern Ireland (applying 
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the STOPP criteria) to be 34%. Moreover, those medications prescribed for people aged 70 and 
over roughly cost €6,098,419 or approximately 5.38% of the total pharmaceutical expenditures 
(Bradley et al., 2012). These studies agree that the most frequently prescribed PIMs are proton 
pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs), and long acting 
benzodiazepines (Bradley et.al, 2012; Cahir et al., 2010). Similarly, an American survey study 
conducted from 2000 to 2001 showed that the use of PIMs cost approximately $7.2 billion in US 
health care expenditures (Fu et al., 2007). 
1.4 Assessment Tools Used to Identify PIMs 
There are a large number of different criteria to describe PIMs that can be considered tools 
for evaluation, education, and detection. All were developed and reviewed by experts who 
specialize in and practice geriatric care and are based on evidence-based guidelines and 
published reviews. These tools are based on explicit and implicit criteria. 
Implicit criteria, which are based on clinicians’ judgment, include general questions that alert 
clinicians to factors associated with PIMs. An example is the Medication Appropriateness Index 
(MAI), but it may be difficult and complicated to apply (Pitkala et al., 2012). Implicit criteria 
depend upon healthcare decision-makers who have comprehensive and sufficient knowledge and 
practice in geriatrics to identify and prescribe appropriate medications. So, a large number of 
implicit tools are very time-consuming (Gokula & Holly, 2012). In contrast, explicit criteria 
include lists of drug-related problems and include medications that interact with drug-disease or 
conditions that should be avoided by elderly people. The main advantage of explicit criteria is 
that they are easily applied; drug or disease oriented, and require little or no clinical judgment 
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(Pitkala et al., 2012). However, explicit tools may not necessarily be applicable to specific 
elderly people because individual patients have unique conditions that require customized 
treatments. Explicit tools that are commonly used to evaluate PIMs are the Screening Tool of 
Older Persons’ Prescriptions (STOPP), the Screening Tool to Alert to Right Treatment (START), 
and Beers’ Criteria.  
1.4.1 Beers’ Criteria 
 Beers’ criteria were the first criteria developed to determine the appropriateness of a 
prescribed medication for geriatric patients and became widely used in United States (Beers et 
al., 1991). They were initially developed by Beers and his colleagues to identify PIMs for older 
adults in nursing homes. These criteria were modified and revised in 1997 and 2003 to comprise 
all healthcare settings for older adults receiving PIMs (Beers et al., 1991; Beers, 1997; Dedhiya 
et al., 2010; Fick et al., 2003; Fu et al., 2007; Gurwitz et al., 2003; Gokula & Holly, 2012). In 
2012, Beers’ criteria were updated via the consensus of an 11-member interdisciplinary expert 
panel in geriatrics care and pharmacotherapy (Campanelli, 2012) using the most current 
comprehensive review evidence and ranking these reviews based on quality and strength of 
evidence. Beers’ criteria were supported and published with the support of the American 
Geriatrics Society in 2012 (see Appendix A). The updated Beers’ criteria include fifty-three 
medications or medication classes divided into three categories: potentially inappropriate 
medications and classes, potentially inappropriate medications and classes to avoid in geriatric 
patients for specific diseases and syndromes, and medications to be used with caution in geriatric 
patients (Campanelli, 2012). 
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1.4.2 STOPP and START criteria 
The STOPP and START criteria are commonly used in Europe (see Appendix A). In 
2008, these criteria were created by an interdisciplinary team of 18 experts in geriatric medicine, 
clinical pharmacology, clinical pharmacy, psychiatry, and primary care in Ireland (Gokula & 
Holly, 2012; O’Mahony et al., 2010). These criteria involve two parts. STOPP includes sixty-
five drugs that are indicators to detect PIMS by a list of drug-drug and drug-disease interactions 
that worsen the medical condition of older patients (O’Mahony et al., 2010; Chang & Chan, 
2010; Gokula & Holly, 2012). The medications are categorized based on human physiologic 
systems and by drug classes (O’Mahony et al., 2010; Gokula & Holly, 2012). The START 
criteria tool is comprised of twenty-two medications that are frequently omitted by prescribers 
(O’Mahony et al., 2010; Gokula & Holly, 2012; Chang & Chan, 2010). In essence, the “STOPP” 
division is concerned with potential errors of prescribing commission which includes list of 
medications to be avoided, while the “START” division covers potential errors of prescribing 
omission. In this study, “STOPP” criteria are used along with Beers’ criteria to determine the 
inappropriateness of medication prescriptions. 
1.5 Previous Comparative Studies between STOPP and Beers’ Criteria 
1.5.1 Differences in the features of these tools 
These two explicit criteria have multiple differences, including the specialist teams who 
created the lists, the number of medications listed, and their reasons for considering these 
medications as PIMs. However, the most notable difference is the classification of these 
therapeutic drugs and the frequency of use or availability of drugs worldwide. These two aspects 
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were drawbacks of the 2003 version of Beers’ criteria. In comparison, the STOPP criteria was 
more applicable as it divided drugs into groups based on physiological systems and included 
frequently prescribed drugs among older adults. However, the updated Beers’ criteria of 2012 
included three new classifications of drugs: (1) drugs to be avoided regardless of diagnosis, (2) 
drugs to be avoided in the presence of certain diseases or syndromes, and (3) drugs to be used 
with caution, as well as omitting medications and adding some to new lists. All weaknesses 
documented by numerous critics were modified and improved by the American Geriatrics 
Society (Fick & Semla, 2012) using evidence-based approaches to update their findings. These 
changes make the Beers’ criteria more clear, reasonable, and feasible to apply on a daily basis 
among health care providers, even if the health professionals have not specialized in geriatric 
medicine (Corsonello et al., 2012; Fick & Semla, 2012). 
1.5.2 Studies comparing STOPP with Beers’ criteria 
From 2003 to 2012, most studies that compared the number of PIMs identified using the 
STOPP and 2003 version of Beers’ criteria obtained markedly different results regarding the 
number of PIMs identified, adverse drug reactions related to PIMs, or resultant hospital 
admissions. Therefore, it is very important to present an overview of the differences in the 
previous results. In 2007, an Irish teaching hospital conducted a prospective study that enrolled 
715 admitted critically ill patients transferred from emergency departments, with a total of 4,403 
prescribed medications. The numbers of PIMs identified by STOPP and Beers’ 2003 criteria 
were 336 and 226, respectively. Moreover, the most frequent PIMs prescribed by STOPP were 
long-acting benzodiazepine, tri-cyclic anti-depressants (TCAs), and antihistamines, followed by 
medications that increased the risk of falls. The prevalence of PIMs was higher by STOPP (35%) 
 14 
  
than by Beers’ (25%) criteria (Gallagher & O’Mahony, 2008). Thus, STOPP criteria were more 
sensitive than Beers’ (2003) criteria in determining adverse effects of these medications leading 
to hospital admissions. Furthermore, the identified PIMs contributed to 11.5% (STOPP) and 6% 
(Beers) hospital admissions of the study population (Gallagher & O'Mahony, 2008). Likewise, 
the prevalence of PIMs in an Irish study of emergency department visits by patients over the age 
of 70 due to falls were 44% (Beers’ criteria) and 53% (STOPP criteria) (McMahon et al., 2014). 
In 2008, at a Spanish nursing home, a retrospective six-month study of 81 older adults using 416 
drugs determined that the prevalence of PIMs was 25% and 48% based on Beers’ (2003) and 
STOPP criteria, respectively (Ubeda et al., 2012). 
Differences in the prevalence of PIMS using the STOPP and Beers’ criteria (2003 version) were 
respectively presented as being 21% versus 13–18% in primary care, 34–50% versus 25–32% in 
hospital care at point of admission, and 60% versus 37% in nursing home care in a study of Irish 
healthcare for the elderly (O’Mahony et al., 2010). Another Irish study, published in 2011, 
collected data from two different areas of Ireland at home-care and long-term facilities and 
applied the two sets of criteria at each site. The results also showed a high prevalence and higher 
detection of PIMs by STOPP than by Beers’ (2003) criteria (Byrne et al., 2011). Interestingly, in 
an American study, the prevalence of PIMs (using 2003 Beers’ criteria) was 21.3% to37% 
among outpatients (Zhan et al., 2001; Steinman, et al.,2006), but up to 50% in nursing home 
residents (Lau et al., 2004), and 16.8 in those visiting the emergency department (Meurer et al., 
2010). 
In contrast to these findings, a 2009–2010 prospective observational study in an Indian tertiary-
care hospital was conducted. It concluded that among 540 patients aged ≥60 years, the median 
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number of medications used was 10 drugs. The study also found that 150 drugs and 79 drugs 
were detected by Beers’ (2003) criteria and STOPP criteria, respectively, which provided a 
higher prevalence with Beers’ criteria (24.6%) than STOPP criteria (13.3%) (Vishwas et al., 
2012). In 2011, a comparative study was conducted in Malaysian nursing homes that involved 
211 patients using 989 medications. That study also displayed that Beers’ (2003) criteria detected 
more PIMs than STOPP criteria, 33% versus 24% (Chen et al., 2012). 
A large European study covered different teaching hospitals that provide geriatric services to 
both urban and rural patients in six countries: Switzerland, Spain, Belgium, Italy, the Czech 
Republic, and Ireland. Overall, the average prevalence of PIMs was 51% according to STOPP, 
greater than that detected by Beers’ (2003) criteria (30%) (Gallagher et al., 2011). According to 
Beers’ and STOPP criteria, the range of PIMs differed between cities, with Prague at 22.7% and 
34.7% having the lowest number of PIMs, while Geneva had the highest at 43.3% and 77.3%, 
respectively, confirming the applicability of STOPP in some European countries (Gallagher et 
al., 2011). 
These differences across the published literature regarding performance of these criteria to 
identify PIMs and adverse drug reactions are due to the difference in the features of these criteria 
studies as well as differing elements within each study that affects net results, such as study 
population, study setting, and formulated medications lists for that region (Vishwas et.al, 2012). 
Therefore, any researchers or professionals intending to use or compare the Beers’ and STOPP 
criteria must consider these factors in their observations. Overall, the range of PIMs identified by 
STOPP versus Beers criteria to summarize the aforementioned literature review. 
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However, the new version of the Beers’ criteria is more realistic and accounts for most of the 
same reasons to consider medications as PIMs (Fick & Semla, 2012). Nonetheless, there are still 
minor differences between the criteria, which made an interesting insight for research to continue 
to evaluate their validity and applicability. 
1.6. PIMs in a rural setting 
There are remarkable differences between rural areas in terms of health status and the utilization 
of health services, leading to discrepancies in life expectancy, physician visits, and access to 
health services. It is clear then, that residents who live in urban areas have fewer challenges 
regarding health care needs than their rural counterparts. Compared to urban residents, rural 
dwellers have less diverse services, support, and caregivers, in addition to demographic 
differences in education and socioeconomic conditions, which are influential factors in health 
(Forbes & Edge, 2009). Thus, rural dwellers have poorer health care statuses and shorter life 
expectancies (Pong et al., 2011). 
By 2021, the percentage of older adults will have increased and it is assumed that one in four 
elders will live in a rural zone. In fact, older adults aged 65 and older will comprise 30% to 40% 
of the population of rural dwelling (Forbes & Edge, 2009). Furthermore, Brundisini and 
colleagues’ (2013) review found that the precarious condition of people with multiple illnesses 
has greater potential to worsen if rurally domiciled. 
Aside from increasing the vulnerability of the elderly, rurality should be evaluated as a 
remarkable factor that may affect health care outcomes. Firstly, “rural” has been defined in 
different manners to serve specific purposes; however, Statistics Canada defines “rural areas” as 
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zones that are located outside of urban centers with populations of at least 10,000. Classification 
depends on the type of rural community and accounts for those close to urban cities where 
advanced health care services are provided. Furthermore, it is subdivided into four categories 
based on a census of rural areas (Pong et al., 2011). 
The literature related to the impressions of family physicians and specialists who work in remote 
and rural settings is considerable, providing a rich image of their needs and satisfactions, as well 
as the prevalence of diseases, frequency of utilization of heath care services, and characteristics 
of rural populations, but not their risk of PIMs (Sibley & Weiner, 2011; Toguri et al., 2012).  
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Chapter 2: Study Rationale & Objectives 
2.1 Rationale for Conducting the Study 
The underlying purpose of this research is to assess the quality of medication use among 
older patients. It is clear that special care should be taken when prescribing medications to older 
patients since inappropriate treatment for older adults leads to ADEs, which are still a major 
challenge facing the health care system, leading to frequent hospitalizations, increasing the 
burden on the health care system. Therefore, continuing research to evaluate and attenuate the 
problem of PIMs is necessary to diminish the burden of ADEs. 
A review of the literature reveals that educating prescribers about the appropriateness of the 
medication prescribed leads to a decrease in the use of inappropriate drugs. The frequency of 
inappropriate medications prescribed has been well-documented worldwide over the past twenty-
five years using a variety of tools. However, the assessment of this problem using updated 
criteria is rare throughout Canada, but especially in rural settings. Therefore, this study attempts 
to determine the extent of inappropriately prescribed medications for the older rural adult. 
In this study, the use of both geriatric assessment criteria is unique, as previously, prevalence 
was measured using either STOPP or Beers’ criteria (2003 version), not both concurrently. Since 
STOPP criteria are quite different from Beers’ criteria, prevalence depends on the type of PIM 
criteria used in the research, making comparisons of the data difficult. However, the updated 
Beers’ criteria (2012 version) have many modifications that improve its deficiencies and 
drawbacks, but its relatively recent availability means that few studies have used this updated 
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version yet. Therefore, this study will use the updated version of the Beers’ criteria in addition to 
the STOPP criteria to identify as many PIMs as possible, to derive a truer picture of the 
prevalence of PIMs. 
Previous studies have focused their efforts in various urban health care settings, or do not 
differentiate rural from urban patients, but few studies are concerned with rural health care 
settings when measuring the prevalence of PIM use among older patients. For example, studies 
of medications prescribed to rural populations and the quality of treatment are rare. In this study, 
we attempt to provide information about medication use in multiple hospitals in rural Ontario. 
Overall, this study is motivated by the inequity between rural and urban centers’ health care to 
evaluate the appropriateness of medication use in those rural settings and to gain insight on 
vulnerable patients who suffer from chronic diseases. Using the updated Beers’ criteria and 
comparing it to the STOPP criteria to determine the appropriateness of medications use provides 
novelty in this research since previous studies used the outdated version of the Beers’ criteria. In 
addition, insufficient research has been conducted in a Canadian context. Finally, we focus on 
inpatients, rather than the more commonly studied facilities, making this research unique. 
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2.2 Objectives and Research Question 
The aims of the study are as follows: 
1) Estimate the prevalence of PIMs use among older patients who are admitted to rural 
hospitals using STOPP and Beers’ criteria. 
a. Identify the most frequent PIM category prescribed. 
b. Compare the number of PIMs identified by STOPP to Beers’ criteria as well as 
the total number of PIMs identified by both criteria. 
2) Explore and determine the factors associated with PIMs use in rural elderly inpatients, 
including patient characteristics. 
This study will answer the following question: 
Is the use of PIMs prevalent among older patients who are admitted in rural hospitals? 
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Chapter 3: Methods 
3.1 Literature Review Strategy 
The literature review was conducted using two databases: Medline (PubMed) and Embase 
(Ovid), using the following keywords as synonyms for “elderly” (known as “Mesh Terms” in 
Medline): geriatrics, geriatric, aged, aged 80 and over, senior, elderly, or older. Searches for 
“inappropriately prescribed medications” were based on suggested acronyms from these 
databases: inappropriate prescribing, inappropriate medication, and inappropriate prescription. 
Also, searches were conducted using the following terms in combination with or without the 
previously mentioned keywords: prevalence, epidemiology, rural, health, medication, drug, tools, 
criteria, STOPP/ START, Beers’ criteria, comparison, difference, Ontario, and Canada. All of 
these keywords were used to assure that all articles related to this subject were reviewed. 
3.2 Research Ethics Clearance 
This study was reviewed and approved by the Research Ethics Office of the University of 
Waterloo and the ethics committee of South Bruce Grey Health Centre (SBGHC) institutional 
review board (see Appendix B). 
3.3 Study Setting 
This study conducted in multiple rural hospitals. The setting of this study is the SBGHC, 
which is comprised of four hospitals in southwestern Ontario in the towns of Chesley, Durham, 
Kincardine, and Walkerton. 
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3.4 Study Population 
All patients aged 65 and over admitted to the four hospitals were included during the study 
period. However, re-admitted patients in the same hospital or in other sites of study were 
excluded to avoid recording patient information twice that would result in inaccurate calculations 
of prevalence. Older patients who declined to sign a consent form were eliminated from the 
study population. Otherwise, there were no selection criteria and all older patients were asked to 
participate in this study throughout the study periods. 
3.5. Study Design 
This study was designed as an observational cross-sectional study. The prevalence of PIMs 
use was evaluated once patients were admitted. Patients’ medication profiles were reviewed and 
analyzed carefully to find the required data. In addition, if the health site had electronic medical 
records database facilities, the patients’ medications were screened from there while the patient 
was still hospitalized. Both PIMs screening tools (updated Beers’ and STOPP criteria) were used 
for each patient’s medication lists. Overall, this study was carried out within three months (mid-
January to mid-April, 2014). 
3.6 Study Protocol 
3.6.1 Data collection 
The data were collected when the patient arrived at the hospital (i.e., the data were 
recorded either from a combination of electronic or paper-based medical charts). The home 
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medication lists from each patient was reviewed, as well as the admission medication list. 
Collected data included clinical and demographic patient characteristics: 
 Patient name 
 Age and gender 
 Medical history and current diagnoses (reasons for admission) 
 Number and type of PIMs from home medications as well as admission lists were 
reviewed and recorded to confirm the complete lists of home medications (reasons for 
any missing information were documented) 
 Total number of prescribed medications per patient 
These data were collected upon hospital admission. The medication data included previously 
prescribed medications and over-the counter (OTC) medicines that the patient was administering 
daily just prior to hospital admission. 
3.6.2. Processes of the data collection 
Information was collected through multiple steps at each hospital as follows: 
1. One site had all the admissions lists for all four hospitals. These admissions lists were 
provided and updated on a daily basis and included patient name, age, hospital ID, patient 
room number, and a briefing of the diagnosis upon admission. This method helped assess all 
the admitted patients in all four hospitals until the end of the specified study period. Those 
admissions lists were screened to identify patients aged 65 or older. Once new admissions 
were observed, the researcher went to the site to meet the patients. Often, there were 
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admissions in four sites at the same time so the researcher took rounds through all of these 
sites to recruit patients. 
2. Participants signed the provided the patient consent form (see Appendix C). Based on 
patients’ requests, sometimes the consent letters were left with patients to think about and 
discuss with their family members. Since the target population was of older adults, some 
were not familiar with the requirements of conducting clinical research. Once permission 
was granted, a feedback and appreciation letter was given to the patient (see Appendix D). 
3. Located and assessed patient information from their medical charts. 
4. Excluded the patients who were re-admitted to avoid any duplication in the data by 
screening full patient name and age from the research laptop. 
5. Obtained answers and clarifications from nurses or health records in case of questionable 
information. 
6. Reviewed admission/home medication lists carefully and detected PIMs using Beers’ and 
STOPP criteria. 
7. Recorded other required patient information (as mentioned above) by filling out the 
Microsoft's spreadsheet software Excel in the research laptop. 
3.6.3 Obtaining informed consent from geriatric patients 
The recruiting of hospitalized older adults and asking them to sign a consent form was not 
an easy task in practice. While some were in reasonable health with the competence to sign 
consent forms, most elderly patients admitted to hospital were not well-oriented, so unable to do 
so. This made it unethical to ask for their permission while they were in critical condition. Aside 
from their complex conditions, some were in isolation areas, which increased the difficulty of 
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obtaining consent letters. Additionally, other minor challenges were faced in circulating consent 
forms to the patients. These challenges were overcome by waiting for patients to become 
conscious and for their condition to improve to ask them for permission before their discharge. 
Searching for patients’ family members was an alternate solution. In some cases, there were no 
relatives, so powers of attorney were contacted. 
Before asking patients to sign consent forms, explanations of the purpose of the project, the 
reasons to consent, the kind of information being collected, and the risks and benefits of 
conducting of this research were explained, and all of the patients’ concerns and questions were 
answered. Because of the variety of patients, both acceptances and objections were expected. 
When patients or their relatives refused to take part in study even though the benefits and risks of 
this project had been explained and clarified, their decisions were respected and patients or their 
relatives were never encouraged to change their decisions. However, the reasons for participants’ 
objections were requested and documented if applicable. 
3.6.4 Procedures for screened medications and reported PIMs 
Once a patient was admitted and the consent form was completed, about 25 minutes were 
spent to read and record required information into a research laptop computer. Each case was 
comprehensively studied and the required information completed, because in some cases, the 
home medication list and reason for admission was not confirmed or documented at the time of 
admission, which required rechecking from time to time. Once the entire patient information was 
recorded, a second revision of the patient profile was always done in case some of the required 
information changed. 
 26 
  
After completion of these steps to ensure the dataset was accurate, each criterion was applied 
separately. Then, each PIM identified was highlighted using different colors for each criteria and 
the criterion used to consider the medication as a PIM was also recorded. If both criteria were 
identified as the same medication, it was highlighted with a different color and the different or 
same reasons from both criteria were documented. At that point, the number of PIMs was 
counted for each case. At the end of each week of the study period, all data recorded on the 
Excel sheet on the research laptop were reviewed to ensure the required patient data were 
detected and that the counted PIMs were accurate and complete. 
Data collection and consent form accumulation continued, until data for 50 patients was 
achieved. The data entry was then re-evaluated before closing the excel file. At the end of the 
research period, the entire patient dataset was coded and classified based on electronic 
International Classification of Diseases, v. 10 (ICD-10 codes). At this step, patient information, 
reason for admission, and the number of PIMs were reviewed thrice at different times. Finally, a 
last revision was done when reasons for considering a medication as a PIM and the number of 
PIMs were sorted in criteria tables as presented in the next chapter. 
3.7 Information Security Protocol 
3.7.1 Data security procedures designed for this study 
According to the University of Waterloo Information Security (Policy 8), guidelines and 
procedures were created to protect confidential information and privacy of research participants, 
thus helping the researcher to ensure and maintain information security when the individuals’ 
data were collected and stored. 
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This study was concerned with two main direct personal identifiers: patient name and age. Other 
identification numbers (for example: health insurance numbers and patient profile numbers) were 
not collected. The full patient name and age (first, middle and last name) were required to avoid 
possible duplication in the data should the patient be admitted multiple times either in the same 
hospital, or other sites of this study. 
This information and other data (medical histories and current diagnoses) were coded to be 
anonymized to diminish the risk of re-identification of participants. Personal information was not 
recognized when the data was released for analysis purposes, sharing, or presenting study results. 
The following processes were implemented to confirm data security: 
 The site of study where the patient was admitted was recorded as a letter; for example, 
the first hospital or site A was registered as letter A in the database and so on for the 
remaining sites. 
 Each patient at each hospital was registered as a sequentially alphanumeric case; for 
example, the first patient who was admitted to the first site of study had a code 1A and 
the second patient who was admitted to the same hospital had a code 2A, and so on. 
 Knowledge of medical conditions was required to determine the appropriateness of using 
medications with that medical diagnosis. For this reason, diseases were entered and 
encoded using the ICD-10 codes. 
 28 
  
 The collected data was entered in the research laptop using Microsoft Excel. The data 
analysis spreadsheets were password protected. Moreover, the data were not shared with 
others, and patients were not recognized in either the data analysis or reporting. 
 At all times, data set was stored in a secure place and in secure data-encrypted form. 
3.7.2 Information security followed in this study 
3.7.2.1 Physical security The principal investigator was responsible for keeping the research 
laptop in a safe and secure place during transportation and storage. The laptop was stored in 
a locked cabinet in a locked office located in a secure building (School of Pharmacy). Only 
the principal investigator had access to the secure location using physical and electronic 
keys. During data collection, the laptop was logged out or shut down during periods when 
the principal investigator left the office for any reason. Login accounts and other software 
passwords were never shared with anyone. 
3.7.2.2 Software security Spyware and antivirus software were installed to protect the database 
from any threats. Also, the research laptop was not connected to the internet for any reason 
nor used for personal purposes. Furthermore, data was encrypted on the laptop using 
Truecrypt software. This software protected the confidential files from theft. Once the data 
was encrypted, a password or key was required to access the documents. 
Complex passwords were created for the computer. As well, any documents or servers that 
were used during data collection such as Microsoft's Excel, were password protected. A 
password-protected screen saver was applied to ensure that the laptop locked automatically 
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when it was not active within a specified time. Finally, direct identifier data was erased and 
destroyed in a secure manner to protected privacy (e.g.: secure digital destruction program). 
3.8 Statistical Analysis 
Firstly, the prevalence of PIMs use was measured by collecting the total number of patients 
who had been prescribed at least one PIM, as the numerator divided by the total number of 
patients enrolled in this study within the three month period as the denominator. 
Secondly, the possible factors associated with PIMs use including demographic patient 
characteristics, age, gender, and clinical patient characteristics (number and type of diseases and 
number of medications prescribed) were assessed. These data were expressed as a mean and 
percentages (%). The association between these factors that lead to the use of PIMs was 
identified using logistic regression analysis. The odds ratio with a 95% confidence interval (CI) 
was reported for each of the explanatory variables. A p-value of 0.05 was considered significant. 
Statistical analyses were performed using the IBM SPSS (Statistical Package for the Social 
Sciences), version 22. 
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Chapter 4: Results 
4.1. Study Population Size 
During the three month study period, all 215 age-eligible patients that were admitted at one 
of the four sites were considered for participation in this study, within which 178 signed consent 
forms. However, 31 of 178 were readmitted later within the same study period but excluded from 
eligibility at the second admission to avoid duplication of data. Thirty seven patients declined or 
were unable to provide consent and were excluded. In brief, some patients objected because they 
did not wish to release their information or were enrolled in other research. Furthermore, some 
patients were excluded because they were at the end stage of life or were not competent, or did 
not have relatives or power of attorney to provide consent. 
4.2 Participant Demographics 
Of the study population, 93 (52.2%) were female and 85 (47.8%) were male. The mean 
patient age was 79.09 ± 8.270. The median age of the participants was 80 (65–97) years. Most of 
the patients aged 85 years and older were female (see Figure1). The patient’s demographic 
characteristics are represented in Table 1. 
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Figure 1. Distribution of the study population by age and gender 
Table 1. Patient demographics 
Patient 
Characteristic 
Female 
N= 93 (52.2%) 
Male 
N= 85 (47.8%) 
Total 
N=178 (100%) 
Age    
Mean (SD) 79.90 ± 8.195 78.20 ± 8.309 79.09 
Median 80 79 80 
Age range    
65-69 11 (6.2%) 16 (9.0%) 27 (15.2%) 
70-74 16 (9.0%) 15 (8.4%) 31 (17.4%) 
75-79 17 (9.6%) 13 (7.3%) 30 (16.9%) 
80-84 17 (9.6%) 18 (10.1%) 35 (19.7%) 
85-89 20 (11.2%) 17 (9.6%) 37 (20.8%) 
90 and more 12 (6.7%) 6 (3.4%) 18 (10.1%) 
Risk factors    
Current Smoking 7 (3.9%) 4 (2.2%) 11 (6.2%) 
Non-smoking 86 (48.3%) 81 (45.5%) 167 (93.8%) 
Alcoholic intake 7 (3.9%) 7 (3.9%) 14 (7.9%) 
Non-alcoholic intake 86 (48.3%) 78 (43.8%) 164 (92.1%) 
Obese 9 (5.1%) 5 (2.8%) 14 (7.9%) 
Non-obese 84 (47.2%) 80 (44.9%) 164 (92.1%) 
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4.2.1. Health conditions of patients 
Table 2 demonstrates that 54.5% of the participants had six or more diseases. The mean 
number of illnesses of the study population was 6.16 ± 3.259. Furthermore, most patients aged 
80-89 years had more chronic conditions compared to the other aged groups. 
Table 2. Number of patients in categories of comorbidities by gender and age group 
 
 0-2 disease(s) 
N = 23(12.9%) 
3-5 diseases 
N = 58 (32.6%) 
≥ 6 diseases 
N = 97 (54.5%) 
Total 
Gender     
Female 11 (6.2%) 32 (18%) 50 (28.1%) 93 (52.2%) 
Male 12 (6.7%) 26 (14.6%) 47 (26.4%) 85 (47.8%) 
Age range     
65–69 3 (1.7%) 11 (6.2%) 13 (7.3%) 27 (15.2%) 
70–74 3 (1.7%) 11 (6.2%) 17 (9.6%) 31 (17.4%) 
75–79 6 (3.4%) 12 (6.7%) 12 (6.7%) 30 (16.9%) 
80–84 6 (3.4%) 7 (3.9%) 22 (12.4%) 35 (19.7%) 
85–89 3 (1.7%) 12 (6.7%) 22 (12.4%) 37 (20.8%) 
90 and over 2 (1.1%) 5 (2.8%) 11 (6.2%) 18 (10.1%) 
Total 23 (12.9%) 58 (32.6%) 97 (54.5%) 178 (100%) 
 
More than half of the study population had six or more diseases; of whom 51.55% (50/97) were 
female and 48.45% (47/97) were male (Figure 2). Among all of the age groups, the number of 
patients approximately increased with the number of diagnoses. Consequently, roughly higher 
percentages of all age groups had six or more diseases than did patients with fewer diseases 
(Figure 3). The percentages of patients with six or more diseases were approximately similar for 
patients aged 80 to 84(22/35= 62.9%), those aged 85 to 89 (22/37= 59.5%), and those aged 90 
and over (11/18=61.1%). These three age groups had the highest proportions of individuals with 
six or more diseases, compared with the other age groups. 
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Figure 2. Distribution of the number of diseases per patient by gender 
Figure 3. Distribution of the number of diseases per patient by age group 
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The most commonly reported diseases were a history of cardiovascular disease 
(160/178=89.9%), followed by endocrine diseases (81/178=45.5%), musculoskeletal diseases 
(72/178=40.4%), gastrointestinal diseases (66/178=37.1%), neurological diseases (57/178=32%), 
respiratory diseases (52/178=29.2%), cancer and immune diseases (36/178=20.2%), urogenital 
diseases (34/178=19.1%), and renal diseases (16/178=9%). The distribution of morbidity and 
comorbidity among the study population is represented in Table 3. 
Table 3. Distribution of chronic diseases among the study population 
Disease No. cases (%) Disease No. cases (%) 
Cardiovascular 
HTN 
Hyperlipidemia 
Arrhythmia unspecified 
CAD unspecified 
HF 
MI/ Heart Attack 
Stroke/CVA 
TIA 
Aortic disorders 
DVT 
Peripheral vascular disease 
Cardiomyopathy 
 
123 (69.10) 
64(35.96) 
47(26.4) 
40(22.47) 
26 (14.61) 
24 (13.48) 
24 (13.48) 
11(6.18) 
7 (3.93) 
6 (3.37) 
5(2.81) 
4 (2.25) 
 
Gastrointestinal 
GERD 
Diverticular of intestine 
Liver disorder 
Constipation 
Inflammatory bowel diseases 
Irritable Bowel Syndrome 
Gall bladder, biliary tract and 
pancreas disorder 
GI Haemorrhage 
PUD 
Diarrhea 
 
 
 
36 (20.22) 
12 (6.74) 
6 (3.37) 
5 (2.81) 
4 (2.25) 
4 (2.25) 
4 (2.25) 
 
3 (1.69) 
3 (1.69) 
1 (0.56) 
 Renal 
CKD 
AKD 
Fluid and electrolyte 
imbalance 
 
13 (7.30) 
4 (2.25) 
4 (2.25) 
Neurologic 
Depression 
Dementia 
Sleep disorders 
Anxiety/ Stress 
Cognitive disorder 
Pain unspecified  
PD 
Bipolar disorder 
Epilepsy 
 
 
 
20 (11.24) 
17 (9.55) 
11 (6.18) 
10 (5.62) 
9 (5.06) 
21(11.79) 
5(2.81) 
2 (1.12) 
1 (0.56) 
 
Urogenital disease 
BPH 
Urinary incontinence 
UTI 
Prostate disorder 
 
15 (8.43) 
8 (4.49) 
5 (2.81) 
2 (1.12) 
Endocrine 
DM2 
Thyroid disorder 
DM1 
Addison crisis 
 
 
45 (25.28) 
31 (17.42) 
13 (7.30) 
2 (1.12) 
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Table 3 cont’d 
Disease 
 
No. cases (%) 
 
Disease 
 
No. cases (%) 
Musculoskeletal 
Osteoarthritis 
Rheumatoid arthritis 
Osteoporosis 
Gout 
DDD 
Bursitis 
Polymyositis 
Cramps 
 
49 (27.53) 
35 (19.66) 
23 (12.92) 
17 (9.55) 
4 (2.25) 
3 (1.69) 
2 (1.12) 
2 (1.12) 
Respiratory 
COPD 
Other disorder 
Asthma 
Pneumonia 
TB 
 
 
36 (20.22) 
10 (5.62) 
8 (4.49) 
6 (3.37) 
2 (1.12) 
 
Infection 
Sepsis 
Other infection 
 
2 (1.12) 
3 (1.69) 
Hematologic 
Anaemia 
 
9 (5.06) 
Ophthalmic disease 
Cataract 
Glaucoma 
Other eye disorders 
 
20 (11.24) 
14 (7.87) 
8 (4.49) 
Skin disease 
Cellulitis 
Other 
 
7 (3.93) 
8 (4.49) 
Cancer and immune system 
Skin cancer 
Kidney cancer 
Colon cancer 
Prostate cancer 
Breast cancer 
Leukemia /Myelodysplasia 
Lung cancer 
Tumor, Unspecified 
Lupus 
Liver cancer 
 
 
7 (3.93) 
6 (3.37) 
6 (3.37) 
5 (2.81) 
5 (2.81) 
5 (2.81) 
4 (2.25) 
4 (2.25) 
2 (1.12) 
2 (1.12) 
Falls 
Fractures 
36 (20.22) 
24 (13.48) 
Other 
Edema 
Nutrition disturbance 
Off balance/vertigo 
Syncope 
Failure to cope 
Allergic rhinitis 
Dehydration 
Rare diseases 
Gangrene 
 
5 (2.81) 
4 (2.25) 
2 (1.12) 
2 (1.12) 
2 (1.12) 
2 (1.12) 
2 (1.12) 
2 (1.12) 
1 (0.56) 
 
AF; atrial fibrillation, AKD; acute kidney disease, BPH; benign prostatic hyperplasia, HF ;congestive  heart failure, 
CAD; coronary artery disease, CKD; chronic kidney disease, COPD; chronic obstructive pulmonary disease, CVA; 
cerebral vascular accident, DDD; degenerative disc disease, DM: diabetes mellitus, DVT; deep vein thrombosis, 
GERD; gastroesophageal reflux disease, GI; gastrointestinal, HTN; hypertension, MI; myocardial infraction , PD; 
Parkinson’s Disease, PUD; peptic ulcer disease, TIA; transient ischemic attack, TB; tuberculosis, UTI; urinary tract 
infection 
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The underlying reason for patient admission or patient diagnose upon admission was carefully 
recorded. Table 4 provides a summary of patient conditions with numbers of cases and 
percentages of patients satisfying the condition. Falls (10.76%) and fractures (14.61%) are 
common reasons for geriatric admissions leading to repairs or replacements of hips or other 
limbs; subsequently the number of surgeries increased as seen below in Table 4. As well, a high 
percentage of seniors were admitted with the condition “Failure to cope” (11.80%), which is 
being commonly diagnosed in most of the older adults upon admission, indicating the severity of 
elders’ conditions. 
Table 4. Reasons for hospital admission 
Disease/condition No. (%) Disease/condition No. (%) 
CVA/Stroke 10 (5.62) Gastrointestinal hemorrhage 4 (2.25) 
TIA 5 (2.81) Bowel diseases 7 (3.93) 
Acute coronary 
syndromes 
4 (2.25) Gallbladder, biliary tract and 
pancreas 
4 (2.25) 
Myocardial infraction 7 (3.93) Renal failure  4 (2.25) 
Angina 3 (1.69) electrolyte imbalance/edema 5 (2.81) 
Heart failure 10 (5.62) Dehydration 7 (3.93) 
Cardiac arrhythmia 14 (7.87) COPD/Asthma 3 (1.69) 
HTN 3 (1.69) Pulmonary disorder 5 (2.81) 
Syncope/Off balance 13 (7.30) Pneumonia 18 (10.11) 
Stress/anxiety 3 (1.69) UTI 7 (3.93) 
Delirium 2 (1.12) Infection 2 (1.12) 
Dementia 5 (2.81) Sepsis 5 (2.81) 
Confusion 8 (4.49) Anemia 5 (2.81) 
Failure to cope 21 (11.80) Skin disease  9 (5.06) 
Tremor 1 (0.56) Gout/arthritis 3 (1.69) 
Headache/Migraine 2 (1.12) Post-surgery/rehabilitation 22 (12.36) 
Weakness 17 (9.55) Metastatic cancer- possible 5 (2.81) 
Pain 17 (9.55) Fall 19 (10.67) 
Glucose disturbance 8 (4.49) Fracture 26 (14.61) 
COPD; chronic obstructive pulmonary disease, CVA; cerebral vascular accident, HTN; hypertension , 
TIA; transient ischemic attack, UTI; urinary tract infection. 
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4.2.2. Medication use 
The total number of medications administered was 2,024. The median number of 
medications used was 10 and the mean was 10.96 ± 5.732. The number of medications used 
among the cohort ranged between 0-27 drugs. The number of medications grouped into different 
intervals to determine the polypharmacy in the study population (see table 5). It shows that most 
of older participants are receiving multiple medications, approximately more than five 
medications. Furthermore, most patients used these medications regularly, because there were 
fewer medications (203) to be used as needed (PRN) than used on a daily basis. In addition, 
patients used 53 non-prescribed OTC medications, some of which (multivitamins, vitamin D, 
etc.) were used on a regular basis as well. Additional details concerning the number of 
medications prescribed for each patient, the drug classifications, and frequency of medications 
used are found in Appendix E. 
Table 5. Number of patients in categories of medication use by gender and age group 
 <5 medications 
No. patients (%) 
5-9 medications 
No. patients (%) 
≥10 medications 
No. patients (%) 
Total 
Gender     
Female 14 (7.9) 23 (12.9) 56 (31.5) 93 (52.2) 
Male 10 (5.6) 31 (17.4) 44 (24.7) 85 (47.8) 
Total 24 (13.5) 54 (30.3) 100 (56.2) 178 (100) 
Age range     
65-69 4 (2.2) 6 (3.4) 17 (9.6) 27 (15.2) 
70-74 3 (1.7) 11 (6.2) 17 (9.6) 31 (17.4) 
75-79 4 (2.2) 8 (4.5) 18 (10.1) 30 (16.9) 
80-84 4 (2.2) 8 (4.5) 23 (12.9) 35 (19.7) 
85-89 5 (2.8) 16 (9.0) 16 (9.0) 37 (20.8) 
90 and over 4 (2.2) 5 (2.8) 9 (5.1) 18 (10.1) 
Total  24 (13.5) 54 (30.3) 100 (56.2) 178 (100) 
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As shown in Table 5, only 13.5% of patients used less than five medications, whereas 86.5% of 
patients used five or more medications. More than half of the older adults (n = 100, 56.2%) 
consumed ten or more medications, of whom 56% were female and 44% were male (Figure 4). 
The number of medications used increased in each age group, peaking in the 80-85 group, and 
then declining in the 85–89 group and over 90 group. All age groups contained more people who 
used ten or more medications than those who used few medications (Figure 5). 
 
 
 
Figure 4. Distribution of the number of medications used per patient by gender 
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Figure 5. Distribution of the number of medications used per patient by age group 
4.3 Potentially Inappropriate Medication Use 
4.3.1 Prevalence of PIMs by STOPP, Beers’ and both sets of criteria 
The prevalence of using at least one PIM among the older adults in this study was 62.92% 
(112/178) based on Beers’ criteria, while the prevalence of receiving at least one PIM was 
69.10% (123/178) by STOPP criteria. When both criteria were used concurrently, the proportion 
of using at least one PIM was 73.03% (130/178). Table 6 presents the differences between the 
number of patients administering multiple PIMs compared with types of screening criteria, 
whether these criteria are used individually or together. 
From Figure 6, the concurrent use of both criteria resulted in an increased number of PIMs 
detected per patient, which is equal to the total number of PIMs identified by each set of criteria 
minus the number of medications that both criteria agree upon and considered as PIMs (the 
overlap in the number of PIMs between both criteria), in order to avoid duplication in results. 
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Table 6. Number of patients receiving PIMs using Beers’, STOPP, or both sets of criteria 
 Beers’ criteria 
No. patients (%) 
STOPP criteria 
No. patients (%) 
Beers’ & STOPP 
No. patients (%) 
Patient does not receive PIMs 66 (37.1) 55 (30.9) 48 (27.5) 
Patient receives one PIM 51 (28.7) 55 (30.9) 34 (19.1) 
Patient receives two PIMs 40 (22.5) 36 (20.2) 40 (22.5) 
Patient receives three PIMs 14 (7.9) 22 (12.4) 26 (14.6) 
Patient receives four PIMs 6 (3.4) 4 (2.2) 18 (10.1) 
Patient receives five PIMs or more 1 (0.6) 6 (3.4) 12 (6.7) 
Total 178 (100) 178 (100) 178 (100) 
 
 
 
Figure 6. Distribution of patients by PIM frequency using Beers, STOPP, or both criteria 
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4.3.2. Number of PIMs in each category identified using STOPP, Beers’, or both criteria. 
To detect the medications that should be avoided, 25 of 48 Beers’ criteria were used (29 
of 53 criteria were used to determine medications that should be avoided or used with caution), 
whereas 53 of 65 STOPP criteria were used. As a result, the total number of PIMs identified by 
Beers’ criteria is 202 PIMs (see Table 7), and by STOPP criteria is 240 PIMs (see Table 8). 
Table 7. Number of PIMs identified by Beers Criteria 
 
 
Therapeutic Category or Drug Number of PIMs (%) 
Anticholinergic Drugs  
1. First-generation antihistamines 11 (5.4) 
2. Antispasmodics 1 (0.49) 
Anti-infective  
3. Nitrofurantoin 1 (0.49) 
Cardiovascular  
4. Antiarrhythmic drugs (Class Ia, Ic, III) 2 (0.99) 
5. Digoxin >0.125 mg/day 3 (1.48) 
6. Spironolactone >25 mg/day 7 (3.46) 
Central Nervous System  
7. Tertiary TCAs, alone or in combination 4 (1.98) 
8. Antipsychotics, 1st-(conventional) & 2
nd
 (atypical) generation 12 (5.94) 
9. Benzodiazepines; short, intermediate and long-acting 26 (12.87) 
Endocrine system   
10. Insulin, sliding scale 6 (2.97) 
11. Sulfonylureas, long acting 3 (1.48) 
Gastrointestinal  
12. Metoclopramide 6 (2.97) 
Pain Medications  
13. Meperidine 2 (0.99) 
14. Non-COX-selective NSAIDs, oral 11 (5.4) 
15. Indomethacin 
Ketorolac, includes parenteral 
2 (0.99) 
1 (0.49) 
16. Skeletal muscle relaxants 2 (0.99) 
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AChIs; acetylcholinesterase inhibitors, CCB calcium channel blocker, NSAID; nonsteroidal anti-inflammatory drug, 
SSNI; serotonin and norepinephrine reuptake inhibitors SSRI; selective serotonin reuptake inhibitor, TCA: tri-cyclic 
antidepressant  
Table 7 cont’d 
Medications with specific diseases or syndromes 
17. Heart failure with 
NSAIDs and COX-2 inhibitors 
Nondihydropyridine CCBs 
Pioglitazone 
 
7 (3.46) 
5 (2.47) 
2 (0.99) 
18. Syncope with 
AChEIs 
Tertiary TCAs 
 
2 (0.99) 
1 (0.49) 
19. Dementia & cognitive impairment 
Anticholinergics 
Benzodiazepines 
H2-receptor antagonists 
Antipsychotics, chronic and as-needed use 
 
9 (4.45) 
4 (1.98) 
1 (0.49) 
5 (2.47) 
20. History of falls or fractures 
Anticonvulsants 
Antipsychotics 
Benzodiazepines 
TCAs 
SSRIs 
 
7 (3.46) 
2 (0.99) 
13 (6.43) 
5 (2.47) 
17 (8.41) 
21. Parkinson’s disease 
Antipsychotics 
 
2 (0.99) 
22. Chronic constipation with 
Oral antimuscarinics for urinary incontinence 
Nondihydropyridine CCB 
 
5 (2.47) 
4 (1.98) 
23. History of gastric or duodenal ulcer 
Non–COX-2 selective NSAIDs 
 
3 (1.48) 
24. Chronic kidney disease 
NSAIDs 
 
2 (0.99) 
25. Lower urinary tract symptoms with 
Benign prostatic hyperplasia 
Inhaled anticholinergic agents 
 
 
6 (2.97) 
Total 202 (100) 
Medications used with Caution 
26. Aspirin for primary prevention of cardiac events 8 (15.09) 
27. Dabigatran 6 (11.32) 
28. Mirtazapine 
SNRIs 
SSRIs 
9 (16.98) 
15 (28.30) 
13 (24.52) 
29.Vasodilators 2 (3.77) 
Total 53 (100) 
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Table 8. Number of PIMs identified by STOPP Criteria 
Therapeutic Category or Drug No. PIMs (%) 
Cardiovascular System  
1. Digoxin >0.125mg with impaired renal function 1 (0.41) 
2. Loop diuretic as first line monotherapy for HTN 7 (2.91) 
3. Thiazide diuretic with a history of gout 5 (2.08) 
4. Non selective beta blocker with COPD 1 (0.41) 
5. Diltiazem or verapamil with NYHA Class III/IV heart failure 5 (2.08) 
6. CCB with constipation 7 (2.91) 
7. Aspirin and warfarin without H2 R antagonist or PPI 1 (0.41) 
8. Aspirin with history of PUD 3 (1.25) 
9. Aspirin with doses > 150mg/day 6 (2.5) 
10. Aspirin with no history of coronary, cerebral or peripheral vascular 
disease 
6 (2.5) 
11. Warfarin >12 mo. for first uncomplicated pulmonary embolism 1 (0.41) 
12. Aspirin, clopidogrel, dipyridamole, or warfarin with concurrent 
bleeding disorder 
1 (0.41) 
Central Nervous System and Psychotropics  
13. TCAs with dementia 1 (0.41) 
14. TCAs with glaucoma 1 (0.41) 
15. TCAs with cardiac conduction abnormalities 2 (0.83) 
16. TCAs with constipation 1 (0.41) 
17. TCAs with opiate or calcium channel blocker 4 (1.66) 
18. TCAs with prostatism or urinary retention 1 (0.41) 
19. Long term benzodiazepines (>1 month) 5 (2.08) 
20. Long term neuroleptics with Parkinson’s (>1 month) 2 (0.83) 
21. Long term neuroleptics as long term hypnotics 13 (5.41) 
22. Anticholinergics to treat extra-pyramidal neuroleptic symptoms  1 (0.41) 
23. SSRIs with hyponatremia 14 (5.83) 
24. >1 week use first generation antihistamines 11 (4.58) 
Gastrointestinal System  
25. Diphenoxylate, loperamide, or codeine for diarrhea of unknown cause 3 (1.25) 
26. Diphenoxylate, loperamide, or codeine for infective gastroenteritis 1 (0.41) 
27. PPI for PUD at full therapeutic dose >8 weeks 22 (9.16) 
28. Anticholinergic, antispasmodics with constipation 1 (0.41) 
Respiratory System  
29. Systemic vs. inhaled corticosteroids for moderate-severe COPD 3 (1.25) 
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Table 8 cont’d.  
Musculoskeletal System  
30. NSAIDs with history of PUD or GI bleeding 2 (0.83) 
31. NSAIDs with moderate to severe HTN (>160/100) 2 (0.83) 
32. NSAIDs with heart failure 7 (2.91) 
33. NSAIDs long term for mild joint pain in OA 6 (2.5) 
34. NSAIDs with warfarin 1 (0.41) 
35. NSAIDs with chronic renal failure 2 (0.83) 
36. Long term corticosteroids (>3mo) as monotherapy for RA, OA 2 (0.83) 
37. Long term NSAID or colchicine for gout (if allopurinol okay) 9 (3.75) 
Endocrine system  
38. Beta blockers in DM and frequent hypoglycemic episodes  1 (0.41) 
39. Oestrogens without progestogen in patient with intact uterus  2 (0.83) 
Urogenital System  
40. Bladder antimuscarinics with dementia 1 (0.41) 
41. Antimuscarinic with constipation 5 (2.08) 
42. Antimuscarinic with prostatism 2 (0.83) 
43. Alpha blockers in males with frequent incontinence 7 (2.91) 
Drugs that adversely affect those prone to falls (≥ 1 fall/3mo)  
44. Benzodiazepines 11 (4.58) 
45. Neuroleptics 6 (2.5) 
46. 1st generation antihistamines 5 (2.08) 
47. Vasodilators causing hypotension with postural hypotension  2 (0.83) 
48. Long-term opiates with recurrent falls 7 (2.91) 
Analgesics  
49. Long-term powerful opiates first line for mild to moderate pain 1 (0.41) 
50. Regular opiates > 2 weeks with constipation and no laxative 3 (1.25) 
51. Long-term opiates with dementia unless for palliative care 1 (0.41) 
52.Duplicate Drug Class  
Two concurrent benzodiazepine drugs 5* (2.08) 
Two concurrent NSAID 1 (0.41) 
Two concurrent antipsychotic drugs 2 (0.83) 
Two concurrent opioid drugs 9 (3.75) 
Two concurrent regular use of anticholinergic inhalers 1 (0.41) 
Two concurrent regular use of corticosteroids inhalers 1 (0.41) 
Two concurrent PPI drugs 1 (0.41) 
Two concurrent thiazide diuretic drugs 1 (0.41) 
Two concurrent regular long acting beta blocker inhaler 1 (0.41) 
Two concurrent CCB 1 (0.41) 
Two concurrent antihistamine drugs 2 (0.83) 
Total 240 (100) 
*One triple. AChIs; Acetylcholinesterase inhibitors, CCB; calcium channel blocker, COPD; chronic obstructive 
pulmonary disease, GI; gastrointestinal, H2 R; histamine H2 receptor, HTN; hypertension, OA; osteoarthritis, 
PPI; proton-pump inhibitors , PUD peptic ulcer disease, NSAIDs; nonsteroidal anti-inflammatory drugs, RA; 
rheumatoid arthritis, SSRI; selective serotonin reuptake inhibitors, SNRI; serotonin and norepinephrine reuptake 
inhibitors, TCA; tricyclic antidepressant. 
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However, the number of identified PIMs increased to 330 medications used among 130 patients 
(18 + 7 + 105 = 130) when the medications were screened by both criteria (See Table 9). This 
number (330 PIMs) indicates the total number of PIMs but included the overlap number of PIMs 
on which both criteria agreed. Once these duplications were eliminated, the combined criteria 
yielded 112 medications (see Table 11) that were used by 85 patients (see diagram below). Those 
PIMs are detected by common reasons between two criteria. Even though there are a few 
differences between the criteria, in this case they agree that particular medications should be 
considered PIMs. The exact differences and similarities are elucidated extensively in the 
discussion section. 
Table 9. Cross tabulation of patients identified using Beers’ and STOPP criteria 
B
ee
rs
’ 
C
ri
te
ri
a
 
STOPP Criteria  
 No Yes Total 
No 48 18 66 
Yes 7 105 112 
Total 55 123 178 
Yes: number of patients taking PIMs 
No: number of patients not taking PIMs 
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Table 10. Common rationalizations between the two criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic categories identified  
by both criteria 
No. 
PIMs 
Total 
Nondihydropyridine CCB 
With constipation 
With heart failure 
 
5 
5 
10 
Antispasmodics 
With constipation 
 
1 
1 
Antimuscarinics 
With constipation 
With cognitive decline/dementia 
 
4 
1 
5 
NSAID 
With history of PUD or GI bleeding 
With heart failure 
With chronic renal failure 
Warfarin + long term use for OA 
 
11 
7 
2 
1 
21 
Antihistamines 
Long term use 
With falls and fractures 
With dementia or cognitive impairment 
 
5 
5 
7 
17 
Benzodiazepines 
With long acting and long term use 
With falls 
With dementia 
 
8 
9 
1 
18 
Antipsychotic drugs 
Falls and fractures 
As hypnotics drugs 
Parkinson’s disease 
Dementia 
 
5 
10 
2 
4 
21 
SSRI’s 
With falls or fractures and low Na level 
 
8 
8 
Tricyclic Antidepressants 
With dementia/syncope 
With cardiac conduction abnormalities 
With constipation 
With glaucoma 
With history of falls 
With CCB or opiates 
With prostatism or urinary retention 
 
1 
2 
2 
1 
2 
1 
1 
10 
Digoxin > 0.125 mg with impaired renal 
function 
1 1 
Total  112 112 
CCB; calcium channel blocker, GI; gastrointestinal, PUD; peptic ulcer 
disease, OA; osteoarthritis, SSRI; selective serotonin reuptake inhibitor 
 
130 patients received 330 
PIMs when the results of two 
criteria are combined 
Both criteria identified the 
same 105 patients using PIMs 
85 out of 105 
patients screened and 
agreed on by both 
criteria. 85 patients 
administered 112 
PIMs which were 
identified 
approximately by the 
approximately same 
reasons from both 
criteria; see Table 11.  
Both criteria identified the 
same 105 patients using PIMs 
85 out of 105 patients 
screened and agreed on 
by both criteria .85 
patients administered 
112 PIMs which 
identified 
approximately by the 
same reasons from 
both criteria; see  
Table11.  
 47 
  
4.3.3. PIM classification: most frequent PIMs 
There is disagreement between two criteria in determining the rank of frequent medication 
classes. The most frequently-used medication in both tools is represented by numbers and 
percentages that are calculated by the total number of potentially inappropriate therapeutic drug 
classes divided by the total number of PIMs detected by each tool. As depicted in two pie charts 
(Figures 7 and 8), Beer’s criteria detected benzodiazepines (43) as a frequently prescribed 
inappropriate medications, followed by anticholinergics (33), NSAIDs (26), antipsychotics (21), 
antihypertensive/antiarrhythmic (21), selective serotonin reuptake inhibitors (SSRIs) (17), 
antidiabetics (11), TCAs (10), anticonvulsants (7), and antiemetics (6). 
 
 
Figure 7. Frequency of classes of PIMs identified by Beers’ criteria 
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On the other hand, STOPP criteria show a different arrangement and classification than 
Beers’ criteria. Inappropriate antihypertensive/antiarrhythmic drugs (38) were found to be most 
commonly prescribed, followed by NSAIDs (30), anticholinergics (29), PPIs (23) and 
antipsychotics (23), opioids (21) and benzodiazepine (21), SSRIs (14), antiplatelets/ 
anticoagulants (12), TCAs (10), anti-gout (7), corticosteroids (6), and antidiarrheal drugs (4). 
 
 
Figure 8. Frequency of classes of PIMs identified by STOPP criteria
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4.4 Factors Associated with PIMs Use 
4.4.1 Logistic regression 
Regression models are beneficial to explore the relationship between a dependent or 
response variable and one or multiple independent or predicator variables of interests (Forthofer 
et al., 2007). In this study, three regression models were built to analyze the associations between 
the PIMs screening tools and multiple independent variables, including gender, age, type and 
number of illnesses, and number of medications used. These explanatory predictors were tested 
with the dependent variables, which are Beers’ criteria, STOPP criteria, and both sets of criteria 
used together. Binary logistic regression was selected because the dependent variables’ outcomes 
or responses are dichotomous. Logistic regression uses either 0 or 1 to code dependent variables. 
Here, “1” means that the patients use PIMs, while “0” means they do not (Dobson & Barnett, 
2008). Thus, binary logistic regression can predict the relationship between the use of PIMs 
based on different criteria used and the different expected independent variables. This 
relationship can be interpreted in term of odds ratios and its significance can be tested using 
Wald- tests. 
4.4.2 Interpretation of the results from the three models 
Two of the five independent variables—the number of medications and illnesses—are grouped 
into four classes based on their quartiles. The quartile calculation depends on the percentiles of 
the data distribution, with the first quartile being the 25
th
 percentile or less, the second being the 
25
th–50th percentile, the third quartile being the 50th–75th percentile, and the last comprising the 
>75
th
 percentile). However, the number of medications was not solely divided into quartiles; it 
was also divided based on the definition of polypharmacy (Bushardt et al., 2008). The first 
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quartile was originally 0–7 medications, but it was changed to 0–4 in order to include only those 
who used few medications (see Table 11 for illustrations of complete classes for each categorical 
variable). Moreover, histograms were built for the categorical variables in order to confirm that 
the variables’ distributions were equally divided into four groups (see Appendix F). The 
interpretation is based on Table 11, which summarizes the three logistic regression model 
outputs. The odds ratios, confidence intervals (95%), and statistical significance Wald-tests 
associated with each of the explanatory variables are reported in Table 11. 
Table 11. Binary logistic regression outputs for each model 
 Beers’ criteria STOPP Criteria Combined criteria 
 
OR 
95% 
CI 
P 
value 
OR 
95% 
CI 
P 
value 
OR 
95% 
CI 
P 
value 
Gender
1 
Male 
1.226 
0.508-
2.959 
0.650 1.140 
0.470-
2.765 
0.772 1.508 
0.612-
3.719 
0.372 
Age
2 
65-69 
15.306 
2.448-
95.713 
0.004** 8.395 
1.387-
50.828 
0.021** 5.674 
0.953-
33.771 
0.056* 
70-74 16.638 
2.894-
95.648 
0.002** 8.881 
1.566-
50.365 
0.014** 5.952 
1.079-
32.833 
0.041** 
75-79 14.744 
2.677-
81.211 
0.002** 5.662 
1.070-
29.960 
0.041** 4.438 
0.864-
22.807 
0.074* 
80-84 5.124 
1.052-
24.963 
0.043** 3.071 
0.633-
14.909 
0.164 2.059 
0.451-
9.387 
0.351 
85-89 7.331 
1.489-
36.084 
0.014** 3.352 
0.706-
15.920 
0.128 2.352 
0.528-
10.477 
0.262 
Overall   0.028**   0.177   0.308 
Disease 
Cardiovascular 
1.175 
0.282-
4.898 
0.825 0.987 
0.241-
4.036 
0.985 1.037 
0.241-
4.455 
0.961 
Neurological 2.552 
0.926-
7.034 
0.070* 3.016 
1.019-
8.928 
0.046** 2.804 
0.905-
8.690 
0.074* 
Gastrointestinal 0.502 
0.189-
1.334 
0.167 0.785 
0.287-
2.152 
0.638 0.998 
0.361-
2.758 
0.997 
Respiratory 1.741 
0.657-
4.610 
0.264 2.451 
0.816-
7.360 
0.110 2.022 
0.667-
6.127 
0.213 
Musculoskeletal 1.044 
0.417-
2.616 
0.927 2.079 
0.781-
5.530 
0.143 2.375 
0.888-
6.352 
0.085* 
Urogenital 5.180 
1.234-
21.740 
0.025** 16.554 
2.561-
107.01 
0.003** 9.712 
1.550-
60.870 
0.015** 
Kidney 1.579 
0.338-
7.383 
0.561 3.295 
0.545-
19.931 
0.194 1.660 
0.302-
9.119 
0.560 
Endocrine 1.069 
0.440-
2.593 
0.883 0.841 
0.330-
2.142 
0.717 0.908 
0.352-
2.344 
0.842 
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Cancer and 
immune 
1.753 
0.620-
4.960 
0.290 0.574 
0.207-
1.588 
0.285 0.929 
0.325-
2.657 
0.890 
No. illnesses
3 
4-5 
0.587 
0.166-
2.075 
0.408 1.111 
0.319-
3.868 
0.868 0.859 
0.241-
3.063 
0.814 
6-8 0.628 
0.156-
2.524 
0.512 0.738 
0.172-
3.174 
0.683 0.708 
0.167-
3.002 
0.640 
≥9 0.447 
0.074-
2.682 
0.378 0.269 
0.037-
1.931 
0.192 0.321 
0.047-
2.196 
0.247 
Overall   0.812   0.426   0.649 
No. of drugs
4 
5-9 
3.382 
0.952-
12.006 
0.059* 
2.060 
 
0.634-
6.691 
0.229 3.007 
0.922-
9.807 
0.068* 
10-13 5.493 
1.423-
21.195 
0.013** 2.412 
0.700-
8.309 
0.163 3.899 
1.120-
13.571 
0.032** 
≥ 14 52.384 
9.535-
287.78
5 
0.00*** 21.722 
3.939-
119.78
8 
0.00*** 20.728 
3.907-
109.96 
0.00*** 
Overall   0.00***   0.005**   0.005** 
Footnotes for Table 11 
1
 Female is selected as reference                           *P (0.05-0.10): marginally significant 
2
 90 and over is selected as reference                    **P < 0.05: statistically significant 
3
 (0-4 medications) is selected as reference           ***P < 0.001: statistically highly significant 
4
 (0-3 illness) is selected as reference 
 
4.4.2.1 Interpretation of predictor: gender. The three logistic models corresponding to Beers’ 
criteria, STOPP criteria, and combined both sets of criteria respectively provide no evidence of 
associations between gender and occurrences of PIMs, when controlling for other variables. 
4.4.2.2 Interpretation of predictor: age. Overall, when Beers’ criteria is used, there is a 
statistically significant, association between age and PIMs use (P=0.028), when the other 
independent variables are controlled. Specifically, all sub age groups under 90 have significantly 
higher risks of PIMs than the 90 years and older age group. The highest odds ratio was seen in 
patients aged 70–74 years, who had odds of taking PIMs about 16 times higher than the patients 
aged 90 and over. This significant and strong association is also obvious with patients aged 65– 
69 and 75–79. These groups had odds of using PIMs approximately 15 times higher than patients 
aged 90 and older. Similarly, the odds of using PIMs was significantly higher among patients 
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aged 80–84 and 85–88, compared with patients over 90, although not as strongly as the previous 
ranges of ages. 
Under the STOPP criteria, age is overall not associated with the occurrence of PIMs when 
holding other variables constant. The results are insignificant for the prediction of PIM usage by 
age. However, variations among different age groups exist. For example, patients aged 65–69, 
70–74, and 75–79 have significantly higher risks of taking PIMs than patients aged 90 and 
above, but no difference was found between aged 80–89 or over 90. 
When combined, both sets of criteria provide relatively similar results as the STOPP criteria 
alone. When all other variables are controlled, age is insignificant and does not seem to be 
associated with PIMs use. An internal comparison between age ranges only shows significantly 
higher PIM usage for participants aged 70–74, compared with participants aged 90 and older. 
However, the 65-69 and 75-79 age groups are marginally significant and are insignificant at all 
compared with the reference groups. 
4.4.2.3 Interpretation of predictor: type and number of illnesses. Diverse diseases were 
included in the three models to discover any associations with PIMs use when other independent 
variables are controlled for. Cardiovascular disease is a highly insignificant predictor of PIMs, 
irrespective of the criteria applied. Likewise, endocrine, gastrointestinal, immune system 
diseases and cancer do not predict use of PIMs. The associations between respiratory disease or 
kidney disease and taking PIMs are weak and insignificant, regardless of the criteria used. 
However, while musculoskeletal disease was not associated with the occurrence of PIMs when 
either the Beers’ or STOPP criteria were used, it approached significance and was positively 
 53 
  
associated with PIMs when both criteria were applied simultaneously (OR: 2.375, CI: 0.888–
6.352, p = 0.085*). 
Neurological and urogenital diseases are significantly associated with the likelihood of PIM use. 
Based on the STOPP criteria, the odds of taking PIMs for patients with urogenital diseases is 
16.5 times higher than for patients without this disease; this finding is statistically significant 
when the remaining diseases and other independent variables are controlled for. Under the Beers’ 
criteria or combined criteria, the odds of taking PIMs for patients with urogenital illness are 
about 5.9 times than the one for patients without the disease, which is lower than the result under 
STOPP criteria but it is still significant. On the other hand, the odds of taking PIMs for patients 
with neurological diseases are about three times the odds of those without the disease, as 
detected by the STOPP criteria. When the Beers’ criteria or the combined criteria were used to 
determine the occurrence of PIMs, a predictable association between neurological disease and 
PIMs use still existed but with marginal significance. 
Whether both sets of criteria were applied separately or concurrently, there was no predictable 
association between the PIMs used and number of illnesses when the other independent variables 
were controlled for. Regardless of the type of criteria used, when the different subclasses of 
number of illnesses were compared with the baseline subclass, the association was not present; 
demonstrating that unlike the type of illness, the number of illnesses does not predict PIMs. 
However, number of illnesses and number of medications can be highly correlated; hence only 
one of these two factors may show significance when both are included in a regression model.  
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4.4.2.4 Interpretation of predictor: number of medications. Overall, when controlling for other 
variables, the number of medications is significantly associated with PIMs regardless of the 
criteria used. Patients who consumed 5 or more drugs were already on multiple medications; 
they were further classified into the following sub-categories: 
0–4 Minimal number of medications used (reference subgroup) 
5–9 Low number of medications used 
10–13 Moderate number of medications used 
≥ 14 High number of medications used 
When Beers’ criteria and combined criteria were used to determine the occurrence of PIMs, 
patients who used a low number of medications (5–9) had roughly 3 times the odds of taking 
PIMs, compared to patients with minimal medications (0-4), when holding other variables 
constant, but the power of this association was marginally significant. This association became 
insignificant when STOPP criteria were used to determine the occurrence of PIMs. When using 
the STOPP criteria, no difference in the number of PIMs taken was found between patients with 
less than 5 medications and patients with a low (5-9) or moderate (10-13) number of 
medications. On the other hand, when Beers’ and the combined criteria were used, patients who 
received 10–13 medications had significantly higher risks of PIMs than patients with minimal 
medication use (0-4). More specifically, under the Beers’ criteria, patients who received 10–13 
medications had about 5.5 times the odds of taking PIMs compared to patient receiving ≤4 
medications (P=0.013). Furthermore, when PIMs were determined by both sets of criteria, the 
odds of taking PIMs for patients consuming 10–13 medications were approximately four times 
that of patients who took ≤4 medications (P=0.032). 
 55 
  
Remarkably strong predictors of PIMs were observed in patients who consumed ≥14 
medications, compared to patients who received ≤ 4 medications when other variables were 
controlled for, regardless of the criteria used. Under Beer’s criteria model, the odds of taking 
PIMs for patients who consumed high numbers of medications (≥14) were about 52 times the 
odds of patients who used minimal medication (≤4 medications). Based on the STOPP criteria, 
patients who used ≥14 medications had roughly 22 times the odds taking PIMs of those who took 
minimal medication. Finally, when both sets of criteria were used, patients who took high 
numbers of medications had approximately 21 times the odds taking PIMs than those who 
consumed minimal medications. Indeed, consuming ≥14 medications leads to the highest odds of 
taking PIMs among all of the independent variables. 
4.4.3. Diagnostic tests for three models 
When analysis is performed using SPSS, the outputs include results and accuracy 
measurements of the model. In addition, the output is provided in two blocks, as discussed 
below. The logistic regression model was fitted by including all selected independent variables in 
the model at a single step without removing insignificant variables. 
4.4.3.1 Overall test of the significance of the fitted model. Comparing the three fitted logistic 
models including all the independent variables with the logistic model with only an intercept, the 
fitted models demonstrated more statistically significant improvement than the constant models 
(Beer’s criteria chi square = 72.090, df = 21, P <0.000), (STOPP criteria chi-square = 65.489, df 
= 21, P <0.000), (Combined criteria chi-square = 56.565, df = 21, P <0.000). 
4.4.3.2 Model summary table From the model summary table, the Nagelkerke R square reflects 
the percentage of the variation in the response that can be explained by all included predictor 
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variables. It equals 45.5% and 43.4% when using Beers’ criteria and STOPP criteria 
respectively, while in the model of combined criteria, it is 39.5%. 
4.4.3.3 Deviance residual and residual plots Residual means that the observed and predicted 
probabilities were compared for all possible covariate patterns in order to check the model 
adequacy. One of the residual tests used to examine the fitting of model is deviance residuals 
(Forthofer et al., 2007; Dobson & Barnett, 2008). This test is applied with a p-value to indicate 
the goodness of the fit of the model to the data. A small p- value indicates that the predicted 
probabilities diverge from the observed probabilities, so the fitted logistic regression 
model does not adequately predict the observed outcomes. Thus, the larger the p-value 
leads to the conclusion that the model fits the data well.  
From Table 12, the p- value is greater than 0.05, so we accept the null hypothesis that three 
logistic regression models fit the data well. The deviance residuals are plotted by participants for 
the three logistic regression models (Forthofer et al., 2007; Dobson & Barnett, 2008). The 
residuals are overall very small and randomly scattered between -2 and 2, which again support 
the fitted logistic regression models. (Figures 9, 10, and 11) 
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Table 12. Deviance residual test (deviance testing using t-test) 
 N Mean Std. Deviation Std. Error Mean 
Beers Criteria Model 
Deviance value 178 .0485208 .95736032 .07175719 
STOPP Criteria Model 
Deviance value 178 .0675237 .93219470 .06987095 
Combined Criteria Model 
Deviance value 178 .0899696 .91908605 .06888841 
  
 
 
 
Test Value = 0 
t df 2-tail 
significance 
Mean 
Difference 
95% Confidence Interval 
of the Difference 
Lower Upper 
                       Beers Criteria  
Deviance value .676 177 .500 .04852084 -.0930889 .1901306 
STOPP Criteria  
Deviance value .966 177 .335 .06752374 -.0703636 .2054111 
 Combined Criteria  
Deviance value 1.306 177 .193 .08996963 -.0459787 .2259180 
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Figure 9. Residual plot for Beers’ criteria model 
 
Figure 10. Residual plot for STOPP criteria model 
 
 Figure 11. Residual plot for combined sets of criteria model 
 
 59 
  
Chapter 5: Discussion & Conclusion 
5.1 Prevalence of PIMs When Using Two Criteria Independently 
From among the 178 rural elderly patients enrolled in this study, over 60% used at least 
one PIM regardless of the criteria applied. The prevalence of PIMs truly depends on the criteria 
used; the percentage of PIMs among older adults based on STOPP (69%) is higher than PIMs 
identified by the Beers’ criteria (63%). 
As presented in the literature review, most previous studies used the old version of Beers’ criteria 
(2003) in comparison studies with STOPP criteria, with the result that STOPP criteria identified 
more PIMs than did Beers’ criteria when used in different healthcare settings (Gallagher & 
O’Mahony, 2008; Ubeda et al., 2012; Byrne et al., 2011; Gallagher et al., 2011). Other non-
European studies showed the opposite, finding that Beers’ criteria detected more PIMs than 
STOPP (Vishwas et al., 2012; Chen et al., 2012). Despite applying the same criteria, the conflict 
between the results exists due to differences in drug formularies and healthcare settings. Aside 
from this variance, these studies cannot be compared with the present study because of the 
differences between the previous and updated versions of Beers’ criteria. These modifications to 
the latest version released in 2012 identify more patients with PIMs than did the 2003 version 
(Undela et al., 2014). The restructuring and modification of Beers’ criteria by adding new 
therapeutic drugs and removing other medications is based on clinical evidence and availability 
on the market (Campanelli, 2012). 
Three current studies, with slightly different objectives, but comparing PIMs criteria identified 
using STOPP and the 2012 version of Beers’ criteria were located. Two of these studies reported 
that patients taking PIMs are more readily detected by STOPP than by Beers’ criteria, even 
though they were applied in diverse areas and settings. The first study was carried out in Ireland 
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at 14 long-term care facilities where 732 older adults’ medication profiles were screened and 
reviewed to detect PIMs. The study showed that the predominance of PIMS was higher using 
STOPP (63.7%) than Beers’ (42%) criteria (O'Sullivan et al., 2013). An Australian study 
evaluated the medication profiles of 570 ambulatory patients using three criteria, of which two 
match our criteria. In this study, STOPP was used to detect 1,032 PIMs used by 79% of the 
patients, while Beers’ criteria identified 399 PIMs used by 48% of the patients (Curtain et al., 
2013). In contrast, Italian research provided a disagreement with the previous two studies when 
the two sets of criteria were applied separately. Beers’ criteria detected more PIMs (58.4%) than 
STOPP (50.4%) criteria (Tosato et al., 2014).
 
However, the remarkable idea here is that even 
though these criteria were originally established in different areas; Beers’ criteria in North 
America and STOPP in Europe, the results stand out as being opposite to what has been 
expected. It has been mentioned that these criteria detect more PIMs in the area where they were 
originally established, due to local medication usage. This was first noted in an Irish long-term 
study that posited that more PIMs were detected by STOPP criteria than by Beers’ criteria due to 
the fact that STOPP was established based on an Irish setting (O’Sullivan et al., 2013). This 
general perspective is not absolutely true, especially after the updating of Beers, criteria, which 
was previously considered as the main reason for differences in applicability. In the context of 
this study’s findings, the results of these articles raise important questions about the differences 
in detection of PIMs. Are the features of each tool and/or external inferences related to 
prescribers or health care settings that create disagreements about the performances of these 
criteria? This is discussed extensively below after elucidating the differences between the tools 
and the evaluations of the prevalence of PIMs among rural elders. 
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5.2 Prevalence of PIMs When Applying Two Criteria Concurrently 
The prevalence of patients using at least one PIM exceeded 70% when both criteria were 
applied concurrently in the same setting. When STOPP and Beers’ criteria were used together on 
the same population and setting, they detected 330 prescribed PIMs among 130 patients (73%); 
demonstrating that the sensitivity of detecting PIMs is increased by using these tools together. 
This finding was confirmed by only one recently published study (CRIteria to Assess 
Appropriate Medication Use among Elderly Complex Patients (CRIME)), where using both 
criteria led to the identification of 75% of the population as using PIMs, which approximates the 
present results (Tosato et al., 2014) 
The detection of the proportion of a study population using PIMs is directly amplified when both 
criteria are used concurrently, compared with using each criteria individually. Since using both 
criteria together eliminates any differences between or shortcomings within the criteria, the 
subsequent detection of prevalence increases. According to epidemiological theory, this indicates 
that the net sensitivity is increased, while the net specificity is decreased, when compared to 
using each set criteria separately. In most health care settings, several tests are done concurrently 
upon admission to ensure correct test results for the patient. Using both criteria simultaneously 
increases the probability that a patient will have a positive result since a positive result can be 
found using either one or both of the criteria. Furthermore, the test result is considered negative 
when all tests provide negative results (Gordis, 2009). It is very important to apply both criteria 
concurrently when detecting PIMs on each individual since there are some differences between 
the criteria. This method will help decision-makers to note any medications that could be 
considered as PIMs, so that their decisions will be based on full knowledge about potential PIMs, 
regardless of differences between criteria used to detect them. 
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5.3 Rural Study Populations 
The study population was comprised of acutely ill patients aged 65 years and older with a 
history of chronic diseases who presented to the in-patient departments of four hospitals. More 
than half of all patients had six or more chronic diseases, irrespective of gender. Generally, the 
most prevalent disease was cardiovascular disease and the main co-morbidity was hypertension 
(HTN), affecting approximately 70% of the patients. Most patients had other heart conditions or 
complications such as coronary artery disease (22.47%), arrhythmia (26.4%), history of stroke, 
and/or heart failure. Their history of chronic disease included endocrine disturbances largely due 
to the high prevalence of diabetes mellitus. Approximately comparable percentages of skeletal, 
muscle, and gastrointestinal (GI) diseases such as gastroesophageal reflux, arthritis, and/or 
osteoporosis were found. Similarly, neurological disorders and respiratory disease were 
distributed among this population. The majority of chronic neurologic diseases were mood 
disorders, including depression and anxiety, followed by dementia, and cognitive disorders. 
Chronic obstructive pulmonary disease (COPD) was the most common respiratory illness among 
the study population. It was noted that the distribution proportions of cancer and autoimmune 
diseases are roughly equal to the proportion of urogenital disorders, such as benign prostatic 
hyperplasia (BPH), urinary incontinence, and frequent urinary tract infections. While other 
diseases exist, they were not numerically comparable with the above-mentioned conditions. 
A major factor leading to the risk of taking a PIM is the use of multiple medications. The 
participants in this study tended to take more than 10 medications, and this number rose to 27 in 
one case. As a result, polypharmacy is a significant problem that creates subsequent issues, for 
instance, drug-drug interactions or contraindications. There were many patients admitted with 
one of the categories of drug interaction which increased the toxicity of some medications (based 
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on Lexicomp, a compilation of clinical drug information to promote medication safety). For 
example, a patient who used tiotropium and ipratropium inhalers together, suffered from urinary 
retention, constipation, tachycardia, and dry mouth due to additive anticholinergic effects. 
Tiotropium was also prescribed with hydroxyzine, cetirizine, prochlorperazine, solifenacin, or 
haloperidol that also increased the risk of anticholinergic effects. Furthermore, it is important to 
mention that duplication of medications from the same therapeutic categories was taken, such as 
patients using concurrently three types of diuretics or antipsychotic drugs. 
It is necessary to see admitting participants from different perspectives. The implication of 
geographic residency differences in terms of rural older people’s health status is a very essential 
health concern. This study revealed the wide use of PIMs among rural people recently admitted 
to hospitals. This reflects and provides an overview image about medication management among 
older adults in rural areas and not specifically about those inside hospitals or discharged patients. 
Prescribing excess medications results in consequences of increased ADEs and unnecessary 
polypharmacy, which reduce patients’ quality of life and the quality of healthcare. 
5.4 Comparisons between Rural and Urban Data in the Literature 
The prevalence of PIMs has been investigated in some regions in Canada. Some of the 
published studies reported different proportions of PIMs; for example, in 1995–1996, a study 
reported that 54.7% of 2,633 patients who live in 71 long-term care facilities in Quebec City 
were taking PIMs (Rancourt et al., 2004). A large retrospective study done in Ontario compared 
the prevalence of PIMs prescribed to community-dwelling and nursing home residents in 2001. It 
found that medications that should be always avoided or that are rarely appropriate were 
prescribed more often and were more prevalent in the community (3.31%) than in nursing homes 
(2.26%). The reason for the increased percentage of inappropriate medications prescribed in 
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community-dwellers was attributed to the medication review programs decreed in Ontario 
nursing homes (Lane et al., 2004). A study conducted in primary care in southern Ontario, 
including rural and urban patients found that 16.3% of 777 patients had at least one PIM 
(Howard et al., 2004). However, it is difficult to compare those data with that of the present 
study, due to the differences in criteria and methods that were used. Most of those studies are 
outdated as well. Recently, the Canadian Institute for Health Information (CIHI) published a 
report including the general results of a survey of the medications used by seniors across Canada. 
This report used updated Beers’ criteria to find that the rate of using at least one PIM among 
older adults across Canada ranged from 20.1% to 39.1% and the rate of PIM use in Ontario was 
22.6% in 2012 (Canadian Institute for Health Information, 2014). Again, a comparison could not 
be made with those results since the measurement of prescribed PIMs was conducted by rate and 
the presented study measured the proportion of PIMs that were prescribed. 
Even though different studies have been conducted in rural areas in the world, each rural setting 
is diverse for many reasons. These differences start with the country in which the study was 
conducted and extend to other aspects; for example, the quality of healthcare, lifestyles, 
facilities, infrastructure, and access to healthcare, among others. Also, when attempting to use 
those studies for comparison, the studies’ designs must be considered and analyzed, including 
such factors as sample size, setting, patients’ demographics, and other considerations. Regardless 
of these variables, analyzing studies in different parts of the world enables the finding of clues 
about the increase in PIMs, especially in rural areas. For instance, using the latest version of 
Beers’ criteria in a Nigerian rural tertiary hospital, the prevalence of PIMs was found to be 
25.5% with 66 PIMs in 56 patients (Fadare et al., 2013). This outcome was much lower than 
what was detected in this study, despite a roughly similar sample size (220 patients). However, it 
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is very important to note that 837 drugs were utilized in the Nigerian study with the patients 
using a mean of 4 medications. In our study, the mean was 10 medications; a huge difference in 
terms of polypharmacy. Similarly, in a rural community health center in Taiwan, the prevalence 
of PIMs was low (27.5%, 2003 version Beers’ criteria) with patients using an average of 4 drugs 
(Lin et al., 2011). Although these studies cannot be compared as equivalents, they collectively 
demonstrate that when the number of drugs prescribed increases per patient, the possibility of 
being prescribed a PIM also increases. 
In addition, factors other than polypharmacy might contribute to the number of PIMs taken 
within a population. These factors are not related to patients’ conditions, but are external factors 
that might contribute to an increase in the number of prescribed PIMs; and they vary based on 
regional differences. For example, a study in 2007 confirmed a difference between outpatients in 
rural settings, who used significantly more PIMs than did their urban counterparts. In addition, 
there were variations in the prescribing quality among rural areas, due to the variations in the 
quality and access to healthcare services (Lund et al., 2013). 
The literature concerning differences between rural and urban areas, in terms of external factors 
that lead to an increase in the prescribing of PIMs, especially in rural Ontario is sparse. A 
retrospective study done in 2002 reported that researchers in a small rural hospital recommended 
increased access to diagnostic examinations and enhanced management of heart failure in 
primary care settings. (Sanborn et al., 2005) Another study conducted in 2004 compared urban 
and rural settings, in terms of the prevalence of pain among patients in southeastern Ontario. 
While there was a high prevalence of pain in both urban and rural areas, rural people used fewer 
healthcare services (Tripp et al., 2006). In addition, some studies evaluated the challenges and 
feelings of health care providers. One of these studies indicates that non-trained geriatric/family 
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physicians were more likely to prescribe multiple medications and PIMs than geriatric 
practitioners in a rural U.S. nursing home (Monroe et al., 2011), whereas another study of rural 
and urban family physicians in Ontario found that neither certification nor the amount of time 
elapsed since graduation were significantly associated with the prescribing of PIMs (Howard et 
al., 2004).  
The literature was consistent, as all of these studies sought to demonstrate that rural areas 
demanded more attention and that probably some external factors related to PIMs’ use existed 
only in rural and remote areas. As a result, some studies evaluated uncontrolled external factors 
that might contribute to the increase in the number of PIMs prescribed among rural older adults. 
This study has been designed in a manner to provide more perceptions about the magnitude of 
using PIMs among rural populations, not about the reasons why PIMs are prescribed or the 
occurrence of prescribed PIMs inside those four hospitals. However, these published articles that 
focus on rural areas provide some reasons to consider the differences between rural and urban 
areas. Further research was required in order to confirm if those external factors contributed to 
the increased number of PIMs used. Finally, it is very important to emphasize that this issue is 
not limited to rural areas, but is becoming a global concern. 
5.5 Comparison Between Beers’ and STOPP Criteria 
5.5.1 Frequency of classes of PIMs identified by Beers’ criteria 
Our study’s findings present the controversy of the types of frequent PIMs prescribed, 
according to the STOPP and Beers’ criteria. After conducting our research, the PIMs were 
aggregated and categorized based on the therapeutic drug class for each set criteria, and 
ultimately 14 therapeutic categories were determined. However, the arrangement and types of 
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those classes are disputed due to the differences in the features of both Beers’ and STOPP 
criteria. This is discussed in more detail. 
First, benzodiazepine drugs represent the majority of PIMs prescribed, accounting for 21% of the 
total PIMs, based on Beers’ criteria. Recently, the use of benzodiazepine as hypnotic drugs has 
increased, despite evidence in the literature that strongly recommends avoiding all types of 
benzodiazepines (from short- to long-acting ones) because older adults are more sensitive to 
them and take longer to metabolize them (see Appendix A for the full criteria under independent 
diagnosis). Benzodiazepines are also mentioned under the dependent diagnosis section (see 
Appendix A), where it is recommended to be avoided with dementia/cognitive impairment and 
delirium conditions, as well as in patients with a history of falls or fractures, according to Beers’ 
criteria. In this study, it was observed that the following benzodiazepines were the most 
frequently prescribed: alprazolam, oxazepam, clonazepam, flurazepam, temazepam, diazepam, 
and chlordiazepoxide. 
In the literature, benzodiazepines groups have been under scrutiny since the prescribing of these 
groups has increased and are being inappropriately used among the elderly. A 2003 study 
measured the prevalence of PIMs using different assessments and found short-acting 
benzodiazepine prescriptions are the most frequent PIMs in the long-term-care community in 
southern Ontario, Canada (Howard et al., 2004). A retrospective study done with elders in 
Quebec found that 44% of the elderly who received a benzodiazepine prescription had 
previously had at least one inappropriate benzodiazepine prescription. As a result, older adults 
are vulnerable to hospitalization or visiting emergency or ambulatory care and are at an increased 
risk of benzodiazepine interactions with other medications compared with patients who had 
appropriate benzodiazepine prescriptions. Inappropriate use of benzodiazepine leads to 
 68 
  
significantly increased health costs per patient, which are estimated to be $3,076 per year 
compared with patient taking appropriately prescribed benzodiazepine (Dionne et al., 2013). This 
result was based on previous study data showing that nearly half of community-dwelling adults 
who used benzodiazepine used it inappropriately, and 23% of them had a second benzodiazepine 
prescription or another drug that interacted adversely with benzodiazepines. Also, it was found 
that the patient aged 75 and older were a higher risk of use benzodiazepines for long term than 
patients aged between 65 and 74 (Préville et al., 2011). Even after Beers criteria was updated and 
tremendous research efforts was conducted on benzodiazepines, benzodiazepines are still the 
most frequently prescribed PIMs. 
The second most common PIMs are anticholinergic drugs, which consist of antihistamines, 
antispasmodic, antimuscarinics, and anticholinergic inhalers, which collectively comprise 16% 
of the PIMs identified in this study. Like benzodiazepine, these drugs are mentioned in different 
places in Beers’ criteria under independent and dependent diagnoses including delirium and 
cognitive impairment in addition to chronic constipation, lower urinary tract symptoms and 
benign prostatic hyperplasia. The criteria provide a list of drugs with strongly anticholinergic 
properties that should be avoided with some conditions. 
The third most common PIM category was NSAIDs, which account for 13% of the PIMs 
identified by Beers’ criteria. These include diclofenac, indomethacin, ketorolac, ibuprofen, 
meloxicam, naproxen, and celecoxib. NSAIDs are found in two sections of Beers’ criteria; in the 
dependent diagnosis section, NSAIDs are linked with heart failure, chronic renal disease, and 
history of gastric duodenal ulcer criteria. 
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Anti-depressant medications comprised thirteen percent of the PIMs identified by Beers’ criteria, 
and they are divided into SSRIs (8%) and TCAs (5%) for study purposes. The main reason for 
this division is to enable a comparison when applying the two criteria. TCAs are found in all 
three sections of the Beers’ criteria. They should be avoided with patients who have a history of 
falls and fractures and with patients suffering from orthostatic hypotension or delirium. In 
contrast, the avoidance of SSRIs is only mentioned in instances of falls and fractures. However, 
both should be used with caution because both enhance hyponatremia. Other drugs administered 
to this study population include escitalopram, citalopram, fluoxetine, paroxetine, and sertraline. 
Examples of frequently used TCAs are amitriptyline, nortriptyline, and imipramine. 
Antipsychotic and antihypertensive/antiarrhythmic drugs each comprises ten percent of 
frequently prescribed PIMs, but they are mentioned in different places in Beers’ criteria. 
Antipsychotics are not a good option for treating older adults, and Beers’ criteria emphasize 
avoiding using these drugs, specifically mentioning them multiple times under two sections 
along with cognitive disorders, falls or fractures, and Parkinson’s disease. Haloperidol, 
perphenazine, prochlorperazine, paliperidone, olanzapine, quetiapine, and risperidone are 
examples of PIMs. Antihypertensive/antiarrhythmic medications are listed under independent 
diagnoses such as antiarrhythmic drugs, digoxin, spironolactone, triamterene, and alpha blockers. 
Alpha blocker drugs should be avoided with syncope and urinary incontinence in women. Other 
antihypertensive/antiarrhythmic drugs such as non-dihydropyridine calcium channel blockers 
(CCBs) are listed with heart failure and chronic constipation. During the screening of the 
patients’ medication profiles, amiodarone, sotalol, digoxin, spironolactone, alpha blockers, 
verapamil, and diltiazem were found. 
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The remaining groups such as anticonvulsant, anti-diabetic, and other drugs not comparable with 
STOPP criteria are categorized differently between the two criteria and are not frequently 
prescribed PIMs, so they will not discussed under frequently prescribed PIMs but under 
differences between criteria. 
5.5.2 Frequency of classes of PIMs identified by STOPP criteria 
Antihypertensive/antiarrhythmic drugs (16%) comprised nearly one-fifth of all PIMs 
identified by STOPP criteria, but are in fifth position in the Beers’ criteria. Indeed, this is 
indicative of the differences in composition of the criteria, as will be discussed later in more 
detail. Briefly, STOPP includes extra criteria of therapeutic classes not found in Beers’ criteria, 
such as diuretics and beta blockers, has duplication of treatment criteria that increases the 
number of PIMs for each group, as well as contributing to all following groups.  
Importantly, both criteria agree that inappropriate anticholinergic or NSAIDs are prescribed most 
frequently. Using STOPP criteria, NSAIDs appear more often than anticholinergic drugs because 
STOPP recommends that it ought to be avoided in patients with severe hypertension, those 
taking warfarin, or for long duration use for gout or joint pain in osteoarthritis. Unlike in Beers’ 
criteria, anticholinergic drugs are not mentioned often in STOPP, but do appear under important 
criteria that it should be avoided in patients prone to falls.  
STOPP criteria present important drugs such as PPIs that are prescribed with equal frequency as 
antipsychotic drugs. The difference between the number of antipsychotic drugs identified by 
Beers’ and STOPP criteria is because STOPP criteria counts duplications. Opioids composed 9% 
more of the identified PIMs by STOPP than Beers’ criteria because STOPP criteria do not 
recommend using long-acting opioids as a first line treatment for non-severe pain. Long-term use 
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of opioids with a history of falls or complaints of dementia, or use of opioids with TCAs or by 
patients with chronic constipation without taking laxatives should be avoided. 
In contrast, antidepressant drugs (SSRIs and TCAs) comprised 10% of all STOPP-identified 
PIMs, which is less than what was determined by Beers’ criteria. This is because neither is 
considered as PIMs in patients prone to falls and fractures. However, the actual number of TCAs 
was not changed because STOPP criteria extensively includes TCAs with different 
conditions/drugs; for instance, avoid TCAs in patients with dementia, cardiac conduction 
abnormalities, prostatism, urinary retention, using opiates or CCBs, one or more of which is 
typically borne by most older adults. Therefore, omitting one important criterion (avoid use of 
TCAs in patients at risk of falls and fractures) does not affect the number of TCAs identified as 
PIMs as compared with those identified using Beers’ criteria. 
Antiplatelets/anticoagulants, anti-gout, and corticosteroids in the remaining groups are not 
comparable with Beers’ criteria due to a difference in criteria. This is discussed comprehensively 
below. Overall, the frequency that medications are identified as PIMs depends on how many 
therapeutic drugs are emphasized and repeated under multiple criteria. 
5.5.3 Number of criteria shared by Beers’ and STOPP 
Differences between the criteria should be analyzed in terms of detecting PIMs and 
identifying any disputes between them. It is fundamental to indicate the percentage of useful 
criteria of those assessments in this study setting. Firstly, 29 out of the total 53 Beers’ criteria 
composed more than half of the criteria used (55%) when medications to be used with caution 
are counted. However, the percentage of Beers’ criteria used to determine medications that 
should only be avoided if both independent and dependent diagnosis sections is reduced to 52% 
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(25/48 criteria). These criteria are identified 202 drugs used by 112 elderly patients. On the other 
hand, 80 % (52/65) of STOPP criteria were used to detect 240 drugs taken by 123 elderly 
patients. These differences in the number of criteria used result in a difference in the number of 
PIMs detected. Consequently, the prevalence of PIMs is extremely affected by these differences. 
5.5.4 Differences in medications identified by Beers’ and STOPP criteria 
Despite the extensive updating of Beers’ criteria, STOPP criteria still detect more PIMs. 
There are multiple explanations behind this discrepancy. First, there are various medications only 
listed in either Beers’ or STOPP criteria. These differences are summarized in Table13 using the 
names of drugs that are found in one of these criteria only. For example, the most obvious 
difference is the PPI group, which is found under STOPP criteria but not in Beers’ criteria. In 
this study population, PPIs such as rabeprazole, lansoprazole, pantoprazole, esomeprazole, and 
omeprazole were misused for a longer term and with higher daily dosage allowances. 
The recent and notable changes to Beers’ criteria make them more relevant today. These changes 
include a new list of medications such as thiazolidinediones, AChEIs, and non-benzodiazepines, 
and include newly marketed medications under medications prescribed with caution for the 
elderly based on recent clinical evidence, such as antithrombotics (dabigatran and prasugrel). 
Beers’ criteria also include new conditions not discussed in STOPP criteria, such as delirium, 
syncope, and insomnia (Campanelli, 2012). In spite of these changes, Beers’ criteria still fail to 
meet the standard set by STOPP due to infrequently used medications. For illustration, 
immediate release nifedipine is no longer used since it is less safe and effective than the extended 
release nifedipine. Another example is short-acting dipyridamole, which is always used in 
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Table 13. Medications listed by either Beers’ Criteria or STOPP Criteria 
Drugs that should be avoided with/without diagnosis 
Beers’ 
criteria 
STOPP 
criteria 
Antiparkinson agents    
Antithrombotic: ticlopidine    
Alpha agonists, central    
Antiarrhythmic drugs    
Disopyramide    
Dronedarone    
Nifedipine, immediate release    
Spironolactone >25 mg/day    
Clopidogrel with concurrent bleeding disorder    
Warfarin for ﬁrst, uncomplicated deep venous thrombosis/pulmonary emboli    
Thiazide diuretic with a history of gout    
Loop diuretic for dependent ankle edema/ﬁrst-line monotherapy for HTN    
Non-cardioselective beta-blocker with COPD    
Aspirin at dose>150mg/day- with no history of coronary, cerebral or 
peripheral arterial symptoms or occlusive arterial event- to treat dizziness not 
clearly attributable to cerebrovascular disease 
   
Aspirin >325 mg/ day    
Beta blocker in combination with verapamil    
Antibiotic: nitrofurantoin    
Thioridazine/ mesoridazine    
Barbiturates    
Chloral hydrate    
Meprobamate    
Non-benzodiazepine hypnotics    
Ergot mesylates, isoxsuprine    
Androgens    
Desiccated thyroid    
Growth hormone    
Insulin, sliding scale    
Megestrol    
Sulfonylureas: glyburide    
Glibenclamide with type 2 diabetes mellitus    
Beta blockers with diabetes mellitus and frequent hypoglycemic events    
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combination with aspirin under the name of Aggrenox, but is no longer used alone. For a 
complete list of infrequent drugs, see the full list of Beers’ criteria in Appendix A. Secondly, 
some criteria in the independent diagnosis section are repeated in the diagnosis section, although 
the new organization of Beers’ criteria is better than the old and better than STOPP criteria. 
5.5.5 Therapeutic categories listed by both criteria but for different reasons 
It is also essential to emphasize that even though some therapeutic categories are 
documented in both criteria, they are mentioned under diverse clinical classifications. Regardless 
of independent diagnosis or similarities between criteria, there are differences found in the 
following groups of drugs with different diagnosis: TCAs, SSRIs, benzodiazepines, aspirin, 
corticosteroids, analgesic drugs (NSAIDs, and opioids). Firstly, TCAs have highly 
Table 13. cont’d 
Drugs that should be avoided with/without diagnosis 
Beer’s 
criteria 
STOPP 
criteria 
Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhea of 
unknown cause/ severe infective gastroenteritis 
   
PPI for peptic ulcer disease at full therapeutic dosage for>8 weeks    
Theophylline as monotherapy for COPD    
Colchicine for chronic treatment of gout if no contraindication to allopurinol    
Mineral oil, oral    
Trimethobenzamide    
Skeletal muscle relaxants    
Heart failure with pioglitazone, rosiglitazone, and cilostazol    
Syncope with AChEIs    
Thioridazine with syncope, epilepsy, and delirium    
Chlorpromazine with syncope, epilepsy, and delirium    
Maprotiline, thiothixene, tramadol with epilepsy    
Anticonvulsants with falls and fractures    
Insomnia with oral decongestants, stimulants, theobromines    
Chronic renal disease with triamterene    
Duplicate drug classes    
AChEIs; Acetylcholinesterase inhibitor, COPD; chronic obstructive pulmonary disease, HTN; hypertension 
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anticholinergic effects and therefore should be avoided under the independent/dependent 
diagnosis of Beers’ criteria. Beers’ criteria stipulate that TCAs should be avoided in patients with 
a history of falls and fractures, delirium, and syncope, while STOPP criteria mentions cognitive 
deficiency, cardiac abnormalities, glaucoma, prostatism/history of urinary retention, and use with 
opiates/CCBs. Likewise, SSRIs are contraindicated in patients prone to falls/fractures in Beers’ 
criteria and under caution when the patient has hyponatremia, while STOPP criteria require that 
it be avoided if the sodium level is less than 130 mmol/L. Thirdly, the benzodiazepine drugs 
identified by Beers’ criteria include short acting and intermediate acting, and are linked with 
different diagnoses, such as dementia or delirium that are not recorded in STOPP criteria. 
Another example in Beers’ criteria is that aspirin should be avoided if more than 325 mg/ day, 
and under caution with a patient aged 80 and over for primary prevention of cardiac events, 
whereas in STOPP, aspirin should be avoided at a dose of more than 150 mg/day and in patients 
with no history of coronary, cerebral, or peripheral arterial symptoms or occlusive arterial events. 
Both criteria agree that the use of analgesic NSAIDs should be avoided in patients with heart 
failure, chronic renal disease, and history of GI ulcers. However, STOPP has additional criteria 
such as that NSAIDs should be avoided in patients taking warfarin, with moderate to severe 
hypertension, and for long-term use for gout and osteoarthritis. Opioids are other analgesics that 
are included in multiple STOPP criteria such as avoidance in patients with recurrent falls, 
dementia, and constipation, as well as use of long-acting opiates or use of opiates with TCAs, 
while Beers’ criteria do not consider that opioids as a group should be regarded as PIMs.  Only 
three of the analgesic narcotic medications are included in Beers’ criteria; meperidine, 
pentazocine, and tramadol. 
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In STOPP, corticosteroid drugs are considered PIMs in two criteria; when used for long-term 
treatment for arthritis and when used systemically rather than inhaled in maintenance treatment 
of COPD, whereas in Beers’ criteria, corticosteroids should be avoided only in patients with 
delirium. STOPP appears to be more specific with anticholinergic inhalers, which 
contraindicates only nebulized ipratropium in patients with glaucoma. In contrast, Beers’ criteria 
stipulate that all anticholinergic inhalers should be avoided with BPH or lower urinary 
symptoms. Both criteria agree that oral antimuscarinic drugs have to be avoided in case of 
chronic constipation or dementia (Beers’ criteria stipulate that anticholinergics should be avoided 
with delirium/dementia diagnosis) while STOPP has two more criteria for patients with chronic 
glaucoma/prostatism. 
Even though both criteria indicate avoidance of metoclopramide in case of Parkinson’s disease, 
Beers’ criteria emphasizes this by mentioning metoclopramide in the independent diagnosis 
section. There are nearly similar criteria for both assessments regarding antipsychotics, but 
Beers’ criteria have additional considerations, which emphasize awareness of those medications 
in patients with dementia/cognitive impairment. In spite of Beers’ criteria mentioning 
anticholinergics more frequently than STOPP criteria, it misses an important criterion: 
anticholinergics should be avoided in patients at risk for falls/ fractures. STOPP includes the first 
generation of antihistamines, which are anticholinergic drugs, under that criterion. Another 
difference is in regard to alpha blocker drugs that STOPP criteria indicate should be avoided 
with urinary incontinence among males, Beers’ criteria stipulate avoidance in females with 
urinary incontinence. 
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5.5.6 Other differences between criteria 
Aside from these differences, STOPP criteria are superior to Beers’ criteria in the last 
criterion, which is that any regular use of two concurrent medications of the same drug category 
should be avoided. Significant duplication of medication was observed during review of patient 
profiles. Therapeutic duplication has been documented and evaluated in multiple studies (Hajjar 
et al., 2007; Page et al., 2010). It might be that duplication of treatment is allowed and 
recommended based in practiced in North American countries compared to European countries. 
This criterion detected 25 duplicated medications considered to be PIMs. This is an important 
reason that enables STOPP criteria to detect more PIMs than Beers’ criteria, resulting in the 
higher prevalence of PIMs when using STOPP criteria. 
However, based on the medications prescribed with caution in Beers’ criteria, three criteria used 
in the present study identified 53 drugs that should be prescribed with caution but not avoided. 
The criteria included a new anticoagulant drug that had been used by nearly 3% of the study 
population. This section includes anti-depressant drugs that were not found in other criteria, such 
as serotonin and norepinephrine reuptake inhibitors (SNRIs) and mirtazapine. However, there are 
some criteria that are already included under avoidance in the STOPP criteria that might increase 
the number of PIMs detected using STOPP, such as aspirin. Aspirin is recommended to be 
prescribed with caution to patients aged 80 and over. Also, if a patient takes SSRIs and has 
frequent drops in sodium levels, SSRIs should be avoided according to STOPP criteria. 
Therefore, STOPP criteria identify more PIMs because it includes some medications under 
avoidance while Beers’ criteria list these medications under the cautionary section. 
In the end, it is important to mention that STOPP criteria seem to be a more implicit tool than 
Beers’ criteria because STOPP lists the general names of the pharmacological drug groups such 
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as antimuscarinic, CCBs, and opiates, while Beers’ criteria lists the specific name of drugs such 
as darifenacin, verapamil, and meperidine of the same therapeutic group. Consequently, some 
medications cannot be considered as PIMs because this particular medication is not included in 
the drug formulary. For more illustration, non-benzodiazepine drugs have been mentioned as a 
PIM, but zopiclone is not listed under this group, while the other listed non-benzodiazepine 
drugs are marketed in the United States. It would be preferable to include zopiclone in Beers’ 
criteria to be suitable for the Canadian drug market (Pharmacist’s Letter/Prescriber’s Letter, 
2012). 
5.6 Predicting Factors Associated with PIMs Use 
Exploring the factors that might be associated with use of PIMs by the study population is 
another main aim of this research. Logistic regression models provide some positively predicted 
factors when PIMs were identified by Beers, STOPP, or both sets of criteria. There was no 
association between gender and the number or type of PIMs used, regardless of the tool used to 
identify them. This lack of gender association has been confirmed in multiple studies (O'Sullivan 
et al., 2013; Vishwas et al., 2012), but other studies show a positive association between female 
sex and using PIMs (Cahir et al., 2010; Gallagher & O'Mahony, 2008). However, Cahir et al. 
(2010) showed a negative association of gender when the odds ratio was adjusted which 
confirms the present result. 
On the other hand, the occurrence of PIMs is significantly affected by the patient’s secondary 
characteristics. Age was a predictor for patients using PIMs using Beers’ criteria to detect PIMs, 
but it was an insignificant predictor using STOPP criteria or both sets of criteria. Regardless of 
the overall age predictions, the significance of the association varies between age ranges and the 
type of criteria used to compare between subjects. All of the criteria used to identify PIMs agree 
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that patients aged 70–74 were more susceptible to use of PIMs than those aged 90 and over. It 
was generally noted that patients aged 90 and older had a lower number of PIMs compared with 
those under 90, regardless of the criteria used. This might be because patients of advanced age 
were taking a lower number of medications compared to those of younger age, since the number 
of PIMs increases directly with the number of medications used. A previous study did find that 
the risk of receiving PIMs decreases with aging (Rancourt et al., 2004). Another explanation 
could be that those patients might be healthier than others or that prescribers preferred to reduce 
the number of medications prescribed for patients in advanced age (Rancourt et al., 2004). 
Further research is required since the number of patients who aged 90 and older were enrolled in 
this study is small. 
Heterogeneity in the literature makes it difficult to consider age as a predicting factor of using 
PIMs. While some emphasize negative associations (O'Sullivan et al., 2013; Cahir et al., 2010; 
Bradley et al., 2012; Byrne et al., 2011) others disagree (Vishwas et al., 2012; Ubeda et al., 2012; 
Undela et al., 2014). Nonetheless, it is not possible to compare these results with the present 
study due to multiple factors: some considered elderly people as those aged 60 and over, which 
results in different PIMs (Undela et al., 2014; Vishwas et al., 2012). Furthermore, different 
analysis procedures such as multivariate logistic regression (Vishwas et al., 2012; O'Sullivan et 
al., 2013; Byrne et al., 2011) or Spearman’s’ rho correlation coefficient (Ubeda et al., 2012) were 
used to determine prediction, which influences the results. Moreover, old versions of Beers’ 
criteria were used (Vishwas et al., 2012; Ubeda et al., 2012) or used only STOPP criteria without 
Beers’ criteria (Cahir et al., 2010; Bradley et al., 2012), affecting the number of PIMs identified. 
Cahir et al. (2010) indicated the presence of an age association, but this association declined 
when polypharmacy was adjusted. Numerous studies evaluating PIMs using different geriatric 
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assessments show variation in results. It is very important to consider the site of study or the 
health care setting where patients are enrolled because each health facility has different patient 
condition levels and this might affect patient clinical characteristics. 
Having multiple illnesses does not necessarily mean that PIMs are among the patient’s 
prescribed medications. In this study, there were no predictable or significant associations 
between the number of illnesses that a patient had and the probability of that patient having 
PIMs, under all sets of criteria. Only two articles discussing the number of diseases provided a 
positive link between using PIMs and the number of illnesses. In-patients who had more than 
three illnesses were found to be more likely to have PIMs than those with fewer illnesses in an 
Indian study (Undela et al., 2014), while a second Indian group found that patients with four or 
more illnesses were susceptible to PIMs (Vishwas et al., 2012). 
Regardless of the number of illnesses, it is extremely important to know what types of diseases 
patients have, regardless of whether patients have multiple illnesses. Generally, patients who 
have neurological or urogenital diseases are more susceptible to using PIMs than patients with 
cardiovascular, gastrointestinal, respiratory, musculoskeletal, kidney, endocrine, immune system 
diseases, or cancer. Even though some of these diseases have associations with PIM usage, the 
associations are weak compared to those of neurological or urogenital diseases. Regardless of the 
criteria used, neurological and urogenital diseases had positive, significant associations, except 
that the significance of neurological diseases was reduced when using the Beers’ criteria and 
combined criteria models. 
One of the prominent predictors leading to the increased prevalence of PIMs is prescribing 
multiple medications to older adults, as all of the results for the different assessment models 
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agreed that the number of medications consumed had a statistically significant correlation with 
the occurrence of PIMs. In particular, patients who take fourteen or more drugs are much more 
likely to take PIMs compared to patents taking four or less medications. The number of 
medications used under both sets of criteria, whether used separately or combined, not only 
provides positive results but also has extremely significant associations. On the other hand, the 
three models differ between the two sub-categories of low and moderate number of medications 
consumed. STOPP criteria indicate insignificant associations for either of these medication 
categories, compared to the lowest category of medications used. While the occurrence of PIMs 
identified by combined criteria is significantly associated with patients who used ten to thirteen 
medications, the power of this association is reduced to borderline significance when patients 
used five to nine drugs. 
This does not mean that PIMs are exclusive to patients who use multiple medications, because 
patients who receive fewer medications might still have PIMs. In the screened medications list, 
some patients with fewer medications still had PIMs because the identification of a PIM does not 
depend solely on drug–drug interactions or contradictions that do increase with the number of 
medications used. Thus, all patients’ medications should be screened at the same level, but the 
focus should be on patients who use multiple medications. It is necessary to report patients who 
receive ten to thirteen medications (moderate use) as vulnerable to using PIMs, and patients who 
use 14 or more medications (high use) as having a strong probability of using PIM, regardless of 
the tools used. All articles discussing PIMs considered polypharmacy the chief predictor, with 
some finding that more than five or more than ten prescribed medications should be used to 
predict PIMs (Vishwas et al., 2012; Ubeda et al., 2012; Cahir et al., 2010; Byrne et al., 2011; 
Undela et al., 2014; O’Sullivan et al., 2013). 
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Finally, the occurrence of PIMs unrelated to detectable criteria is not associated with gender or 
the number of illnesses. However, age depends on the criteria used; it is positively associated 
with taking PIMs only under Beers’ criteria, but not when using the remaining criteria models. 
However, when the age categories are scrutinized, patients aged 70–74 are the group most likely 
to have PIMs, regardless of the criteria used. Similarly, patients taking more than 14 medications 
are significantly more probable to take PIMs, compared to patients who take fewer medications. 
Furthermore, there was no significant association between PIM usage and particular diseases, 
excluding urogenital and neurological diseases. All of the criteria sets showed a significant 
association between taking PIMs and urogenital diseases; however, the significance of the 
associations differed for neurological illnesses, based on the criteria applied. In fact, some of 
these findings are consistent with previous studies, but variations might depend on the study 
design and analysis, type of assessment for PIMs, heath care departments, and study site. Also, 
the patient’s health status may have enhanced risk of PIMs prediction when in a critically ill 
condition. 
5.7 Limitations 
Despite this study providing crucial findings to determine the extent of PIMs in older patients 
admitted to rural hospitals, some limitations may exist. Selecting sites that have never conducted 
such medication reviews among admitted older patients, and perhaps unfamiliar with geriatric 
medication use guidelines or tools, may have resulted in the high prevalence of this problem. 
However, the intention was to determine the extent of PIMs use in a rural population. In 
addition, reporting and disseminating the results to the prescribers will increase awareness of 
medications that are probably harmful to the elderly. Another limitation is seemed that sample 
size of the study population that resulted in a large range of confidence interval values. However, 
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this population represents the maximum total number of eligible patients (less those who 
declined to participate) that could be recruited over the three month period. In addition, a number 
of patients were readmitted multiple times, but were excluded from our study for their next 
hospital visits. Moreover, each of the rural areas has a small population and hospital capacity 
compared with urban hospitals. Therefore, we asked multiple rural southwestern hospitals to 
participate in the study to cover the largest number of rural older patients who were recently 
admitted to the hospital. 
While the study aimed to explore factors associated with the increased use of PIMs, it did not 
evaluate all factors leading to the prescribing of PIMs. Some of the factors include the rationale 
behind the prescribing of these medications, socioeconomic issues, and the prescribing patterns 
of clinicians. In this study, the main focus was to evaluate the extent of PIMs in rural elders. 
Investigation of those factors would require different study designs and data collection resources. 
The goal of this study was not to investigate discharge medications or the patterns of prescribing 
medications in hospitals. Rather, these hospitals were employed as capture points to determine 
the prevalence of the use of PIMs in older rural residents recently admitted to these hospitals. 
This kind of study also required a different study design and implementation.  
Despite the study’s challenges, this study has delivered some valuable information about use of 
PIMs used by older adults admitted to rural hospital, where data has been sparse. Enrolling 
patients from different four sites increased the generalizability of the results for rural older adults 
in rural southwestern Ontario. Sufficient medical information and details related to the patients’ 
conditions were available to judge whether medications were PIMs. This study could be the first 
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step to establish future research projects, such as interventions to reduce the prescribing of PIMs 
and evaluation of other external factors that might contribute to the use of PIMs. 
5.8 Conclusions 
Despite massive research efforts, PIMs still appear to be a globally crucial issue that needs 
further efforts to be resolved. The study used two well-documented criteria to evaluate the 
performance of these criteria and investigate the prevalence of PIMs at a site that has never been 
evaluated for the appropriateness of medication prescribed for the elderly. More than 60% of the 
rural elderly in this study take at least one PIM, regardless of which criteria are used. STOPP 
criteria were more likely to detect PIMs than Beers’ criteria because they differ in features, 
causing dissimilar results in terms of prevalence, number of PIMs, and most frequent therapeutic 
category prescribed. However, those discrepancies were negated by applying both criteria 
simultaneously, resulting in the detection of PIMs in over 70% of admitted patients. The most 
frequent PIMs are cardiac and benzodiazepine drugs that are essential to review before the 
patient receives them. Secondly, this research explored factors that predict the occurrence of 
PIMs based on criteria use. Patient age (only with Beers’ criteria), number of medications, and 
presence of neurological/urogenital diseases were associated with an increased probability of 
taking PIMs. Although this study estimated the extent of PIMs and discussed important 
distinctions between two assessment tools, continued research is required to evaluate this 
problem and other contributing factors in various health care settings since PIMs represent a 
serious health threat to older adults. 
 
 85 
  
5.9 Future concerns and recommendations 
This research evaluated concerns about the appropriateness of medication prescribed for the rural 
elderly. This issue persists internationally despite considerable research effort that led to 
proposed solutions. Thus, study findings would not be clinically meaningful if some solutions 
were not taken into consideration. There is a gap between evidence-based guidelines/criteria and 
translation of this knowledge and employment into professional practices, particularly for 
geriatric patients. It is necessary to implement educational or computerized interventions to 
reduce the number of prescribed PIMs. These criteria could be converted to a computerized 
database and incorporated into pharmacist and physician entry order program, medication 
reconciliation program, or any other health care system. This would alert prescribers who are not 
specialists in geriatrics to potential problems (Monane et al., 1998); their decisions would then 
more likely be based on knowledge, even if their decision is not changed (Beers, 1997). This is 
because each decision is made based on individualized treatment and the criteria are not used for 
conclusively deciding for all patients. Concurrent use of both criteria identified more PIMs and 
eliminated conflicts between criteria. Ongoing studies should continue to evaluate this issue 
using the most recent versions of criteria. Further research is required to evaluate criteria 
performance in predicting adverse drug reactions. Moreover, a periodic medication review 
program should be applied in each health care setting to evaluate PIMs, drug omission, drug-
drug interactions, drug regimen, and correct use of drugs. Prescription quality can be improved 
by decreasing risk factors leading to PIMs, reducing polypharmacy, and providing better specific 
disease management. Duplications in treatment from different therapeutic drug classes were 
detected, particularly with the treatment of insomnia, depression, and neuropathic pain. These 
inappropriate treatments are not identified by criteria, but should be tapered, replaced, or 
discontinued. When neurologic medications are prescribed, a neuro/psycho specialist should be 
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consulted to avoid misuse or abuse and to prescribing the right dose for the right indication. 
Identifying the most frequently used PIM classes will help prescribers to pay greater attention 
when prescribing for the elderly, and may facilitate research into creating treatment algorithms 
that address that group of medications. PIMs continue to be prescribed for frail older adults. 
Further research is required to eradicate the continuation of this problem. 
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Appendix A: Criteria Lists 
i Beers’ Criteria 
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ii STOPP Criteria 
The following drug prescriptions are potentially inappropriate in persons aged ≥65years of age. 
 
Cardiovascular System 
1. Digoxin at a long-term dose >125 ag/day with impaired renal function  
2. Loop diuretic for dependent ankle edema only; i.e. no clinical signs of heart failure (no evidence 
of efficacy, compression hosiery usually more appropriate). 
3. Loop diuretic as first-line monotherapy for HTN (safer, more effective alternatives available). 
4. Thiazide diuretic with a history of gout (may exacerbate gout). 
5. Non-cardioselective Beta-blocker with Chronic Obstructive Pulmonary Disease (COPD) (risk of 
increased bronchospasm). 
6. Beta-blocker in combination with verapamil (risk of symptomatic heart block). 
7. Use of diltiazem or verapamil with NYHA Class III or IV heart failure (may worsen heart 
failure). 
8. Calcium channel blockers with chronic constipation (may exacerbate constipation). 
9. Use of aspirin and warfarin in combination without histamine H2 receptor antagonist (except 
cimetidine because of interaction with warfarin) or proton pump inhibitor (high risk of 
gastrointestinal bleeding). 
10. Dipyridamole as monotherapy for cardiovascular secondary prevention (no evidence for 
efficacy). 
11. Aspirin with a past history of peptic ulcer disease without histamine H2 receptor antagonist or 
Proton Pump Inhibitor (risk of bleeding). 
12. Aspirin at dose >150 mg day (increased bleeding risk, no evidence for increased efficacy). 
13. Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or occlusive event 
(not indicated). 
14. Aspirin to treat dizziness not clearly attributable to cerebrovascular disease (not indicated). 
15. Warfarin for first, uncomplicated deep venous thrombosis for longer than 6 months duration (no 
proven added benefit). 
16. Warfarin for first uncomplicated pulmonary embolus for longer than 12 months duration (no 
proven benefit). 
17. Aspirin, clopidogrel, dipyridamole, or warfarin with concurrent bleeding disorder (high risk of 
bleeding). 
Central Nervous System and Psychotropic Drugs 
18. Tricyclic antidepressants (TCA’s) with dementia (risk of worsening cognitive impairment). 
19. TCA’s with glaucoma (likely to exacerbate glaucoma). 
20. TCA’s with cardiac conductive abnormalities (pro-arrhythmic effects). 
21. TCA’s with constipation (likely to worsen constipation). 
22. TCA’s with an opiate or calcium channel blocker (risk of severe constipation). 
23. TCA’s with prostatism or prior history of urinary retention (risk of urinary retention). 
24. Long-term (i.e. >1 month), long-acting benzodiazepines e.g. chlordiazepoxide, flurazepam, 
nitrazepam, chlorazepate, and benzodiazepines with long-acting metabolites e.g. diazepam (risk 
of prolonged sedation, confusion, impaired balance, falls). 
25. Long-term (i.e. > 1 month) neuroleptics as long-term hypnotics (risk of confusion, hypotension, 
extra-pyramidal side effects, falls). 
26. Long-term neuroleptics ( >1 month) in those with parkinsonism (likely to worsen extra-pyramidal 
symptoms) 
27. Phenothiazines in patients with epilepsy (may lower seizure threshold). 
 100 
  
28. Anticholinergics to treat extra-pyramidal side-effects of neuroleptic medications (risk of 
anticholinergic toxicity). 
29. Selective serotonin re-uptake inhibitors (SSRI’s) with a history of clinically significant 
hyponatremia (non-iatrogenic hyponatremia <130 mmol/L within the previous 2 months). 
30. Prolonged use (>1 week) of first generation antihistamines i.e. diphenydramine, 
chlorpheniramine, cyclizine, promethazine (risk of sedation and anti-cholinergic side effects). 
Gastrointestinal System 
31. Diphenoxylate, loperamide, or codeine phosphate for treatment of diarrhea of unknown cause 
(risk of delayed diagnosis, may exacerbate constipation with overflow diarrhea, may precipitate 
toxic megacolon in inflammatory bowel disease, may delay recovery in unrecognized 
gastroenteritis). 
32. Diphenoxylate, loperamide, or codeine phosphate for treatment of severe infective gastroenteritis 
i.e. bloody diarrhea, high fever, or severe systemic toxicity (risk of exacerbation or protraction of 
infection). 
33. Prochlorperazine (Stemetil) or metoclopramide with Parkinsonism (risk of exacerbating 
Parkinsonism). 
34. PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks (dose reduction or earlier 
discontinuation indicated). 
35. Anticholinergic antispasmodic drugs with chronic constipation (risk of exacerbation of 
constipation). 
Respiratory System  
36. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects 
due to narrow therapeutic index). 
37. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-
severe COPD (unnecessary exposure to long-term side-effects of systemic steroids). 
38. Nebulized ipratropium with glaucoma (may exacerbate glaucoma). 
Musculoskeletal System 
39. Non-steroidal anti-inflammatory drug (NSAID) with history of peptic ulcer disease or 
gastrointestinal bleeding, unless with concurrent histamine H2 receptor antagonist, PPI, or 
misoprostol (risk of peptic ulcer relapse). 
40. NSAID with moderate-severe hypertension (risk of exacerbation of hypertension). 
41. NSAID with heart failure (risk of exacerbation of heart failure). 
42. Long-term use of NSAID (>3 months) for symptom relief of mild osteoarthritis (simple 
analgesics preferable and usually as effective for pain relief). 
43. Warfarin and NSAID together (risk of gastrointestinal bleeding). 
44. NSAID with chronic renal failure∗ (risk of deterioration in renal function). 
45. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis or osteoarthritis 
(risk of major systemic corticosteroid side-effects). 
46. Long-term NSAID or colchicine for chronic treatment of gout where there is no contraindication 
to allopurinol (allopurinol first choice prophylactic drug in gout) 
Urogenital System 
47. Bladder antimuscarinic drugs with dementia (risk of increased confusion, agitation). 
48. Antimuscarinic drugs with chronic glaucoma (risk of acute exacerbation of glaucoma). 
49. Antimuscarinic drugs with chronic constipation (risk of exacerbation of constipation). 
50. Antimuscarinic drugs with chronic prostatism (risk of urinary retention). 
51. Alpha-blockers in males with frequent incontinence i.e. one or more episodes of incontinence 
daily (risk of urinary frequency and worsening of incontinence). 
52. Alpha-blockers with long-term urinary catheter in situ i.e. more than 2 months (drug not 
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indicated). 
Endocrine System 
53. Glibenclamide or chlorpropamide with type 2 diabetes mellitus (risk of prolonged hypoglycemia). 
54. Beta-blockers in those with diabetes mellitus and frequent hypoglycemic episodes i.e. ≥1 episode 
per month (risk of masking hypoglycemic symptoms). 
55. Estrogens with a history of breast cancer or venous thromboembolism (increased risk of 
recurrence) 
56. Estrogens without progestogen in patients with intact uterus (risk of endometrial cancer). 
Drugs that adversely affect fallers 
57. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
58. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
59. First generation antihistamines (sedative, may impair sensorium). 
60. Vasodilator drugs with persistent postural hypotension i.e. recurrent >20 mmHg drop in systolic 
blood pressure (risk of syncope, falls). 
61. Long-term opiates in those with recurrent falls (risk of drowsiness, postural hypotension, vertigo). 
Analgesic Drugs 
62. Use of long-term powerful opiates e.g. morphine or fentanyl as first line therapy for mild-
moderate pain (WHO analgesic ladder not observed). 
63. Regular opiates for more than 2 weeks in those with chronic constipation without concurrent use 
of laxatives (risk of severe constipation). 
64. Long-term opiates in those with dementia unless indicted for palliative care or management of 
moderate/severe chronic pain syndrome (risk of exacerbation of cognitive impairment). 
Duplicate Drug Classes 
65. Any duplicate drug class prescription e.g. two concurrent opiates, NSAIDs, SSRIs, loop diuretics, 
ACE inhibitors (optimization of monotherapy within a single drug class should be observed prior 
to considering a new class of drug). 
 
**Reference 
O’Mahony, D., Gallagher, P., Ryan, C., Byrne, S., Hamilton, H., Barry, P., O’Connor M., & 
Kennedy, J. (2010). STOPP & START criteria: A new approach to detecting potentially 
inappropriate prescribing in old age. European Geriatric Medicine, 1, 45–51. 
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Appendix B: Approval letters 
i University of Waterloo 
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ii South Bruce Grey Health Centre 
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Appendix C: Consent Forms 
i University of Waterloo 
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ii South Bruce Grey Health Centre 
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Appendix D: Feedback & Appreciation Letter 
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Appendix E: Full Descriptive Data of Medications used by Patients 
 
Drug Name 
No. 
drugs 
% 
% of 
cases 
No. of 
regular 
drug 
use 
% 
ASPIRIN 76 3.8% 43.2% 76 4.2% 
ACHIS 10 0.5% 5.7% 10 0.5% 
5-ARIS 7 0.3% 4.0% 7 0.4% 
ANTICONVULSANT 26 1.3% 14.8% 26 1.4% 
IMMUNOSUPPRESSANT 5 0.2% 2.8% 5 0.3% 
ANTINEOPLASTIC 1 9 0.4% 5.1% 9 0.5% 
ANTINEOPLASTIC 2 2 0.1% 1.1% 2 0.1% 
ANTIPARKINSON 8 0.4% 4.5% 8 0.4% 
ANTIMALARIAL 3 0.1% 1.7% 3 0.2% 
ANTIGOUT 19 0.9% 10.8% 19 1.0% 
ACEI 53 2.6% 30.1% 53 2.9% 
ARBS 36 1.8% 20.5% 36 2.0% 
PPI 79 3.9% 44.3% 79 4.3% 
ANTIACID 10 0.5% 5.7% 7 0.4% 
DIURETICS 1 95 4.7% 54.0% 158 8.7% 
DIURETICS 2 27 1.3% 15.3% 26 1.4% 
DIURETICS 3 5 0.2% 2.8% 5 0.3% 
NSAIDS 37 1.8% 21.0% 24 1.3% 
ACETAMINOPHEN 59 2.9% 33.5% 18 1.0% 
OPIOIDS 1 53 2.6% 30.1% 26 1.4% 
OPIOIDS 2 17 0.8% 9.7% 11 0.6% 
OPIOIDS 3 2 0.1% 1.1% 1 0.1% 
STATINS 83 4.1% 47.2% 84 4.6% 
EZETIMIBE 14 0.7% 8.0% 13 0.7% 
CHOLESTYRAMINE/FENOFIBRATE 4 0.2% 2.3% 4 0.2% 
ANTIPSYCHOTIC 1 25 1.2% 14.2% 15 0.8% 
ANTIPSYCHOTIC 2 2 0.1% 1.1% 2 0.1% 
BENZODIAZEPINE 1 44 2.2% 25.0% 18 1.0% 
BENZODIAZEPINE 2 6 0.3% 3.4% 4 0.2% 
BENZODIAZEPINE 3 2 0.1% 1.1% 1 0.1% 
SSRI 30 1.5% 17.0% 30 1.6% 
SNRI 15 0.7% 8.5% 15 0.8% 
TCA 11 0.5% 6.3% 10 0.5% 
NON BENZODIAZEPINES 11 0.5% 6.3% 10 0.5% 
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TRAZODONE 20 1.0% 11.4% 19 1.0% 
MIRTAZAPINE 9 0.4% 5.1% 9 0.5% 
MUSCLE RELAXANTS 3 0.1% 1.7% 3 0.2% 
CORTICOSTEROIDS 17 0.8% 9.7% 17 0.9% 
BONE MODIFYING 3 0.1% 1.7% 3 0.2% 
BETA BLOCKERS 60 3.0% 34.1% 60 3.3% 
CCB 1 61 3.0% 34.7% 60 3.3% 
CCB 2 1 0.0% 0.6% 1 0.1% 
DIGOXIN 13 0.6% 7.4% 11 0.6% 
ANTIHISTAMINE 1 28 1.4% 15.9% 6 0.3% 
ANTIHISTAMINE 2 2 0.1% 1.1% 2 0.1% 
ANTIMUSCURINIC 10 0.5% 5.7% 9 0.5% 
ANTISPASMODIC 1 0.0% 0.6% 1 0.0% 
ALPHA BLOCKER 14 0.7% 8.0% 13 0.7% 
ANTIARRYTHMICS 2 0.1% 1.1% 2 0.1% 
ONDASERTON 13 0.6% 7.4% 13 0.7% 
INSULIN 1 15 0.7% 8.5% 15 0.8% 
INSULIN 2 8 0.4% 4.5% 8 0.4% 
METAFORMIN 36 1.8% 20.5% 35 1.9% 
SULPHONYLUREA 13 0.6% 7.4% 13 0.7% 
THIAZOLIDINEDIONE 3 0.1% 1.7% 3 0.2% 
DPP-4 INHIBITORS 10 0.5% 5.7% 10 0.5% 
GLUCAGON LIKE PEPTIDE 1 0.0% 0.6% 1 0.1% 
FERROUS SUPPLEMENTS 25 1.2% 14.2% 25 1.4% 
CALCIUM CARBONATE 27 1.3% 15.3% 26 1.4% 
THIAMINE B1 4 0.2% 2.3% 4 0.2% 
MAGNESIUM GLUCOHEPTONATE 15 0.7% 8.5% 15 0.8% 
POTASSIUM CHLORIDE ER 20 1.0% 11.4% 20 1.1% 
VITAMIN D3 & D2 76 3.8% 43.2% 76 4.2% 
VITAMIN B 12 28 1.4% 15.9% 28 1.5% 
VITAMIN C 13 0.6% 7.4% 13 0.7% 
VITAMIN B6 1 0.0% 0.6% 1 0.1% 
VITAMIN E 5 0.2% 2.8% 5 0.3% 
VITAMINB COMPLEX 2 0.1% 1.1% 2 0.1% 
MULTIVITAMIN 29 1.4% 16.5% 29 1.6% 
FOLIC ACID 2 0.1% 1.1% 2 0.1% 
BISPHOSPHONATE DERIVATIVE 18 0.9% 10.2% 18 1.0% 
ANTIPLATELET 24 1.2% 13.6% 24 1.3% 
ANTIBIOTIC 22 1.1% 12.5% 22 1.2% 
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NITROGLYCERIN 1 31 1.5% 17.6% 17 0.9% 
NITROGLYCERIN 2 7 0.3% 4.0% 3 0.2% 
VASODILATOR 3 0.1% 1.7% 3 0.2% 
LEVOTHYROXINE 45 2.2% 25.6% 45 2.5% 
B2 AGONIST INH 1 38 1.9% 21.6% 18 1.0% 
B2 AGONIST INH 2 11 0.5% 6.3% 1 0.1% 
ANTICHOLENERGIC INH 22 1.1% 12.5% 22 1.2% 
ANTICHOLENERGIC 2 1 0.0% 0.6% 1 0.1% 
CORTICOSTEROID INH 29 1.4% 16.5% 29 1.6% 
CORTICOSTEROID INH  1 0.0% 0.6% 1 0.1% 
ESTROGEN CONJUGATED 
TOPICAL 
2 0.1% 1.1% 2 0.1% 
TOPICAL 1 24 1.2% 13.6% 24 1.3% 
TOPICAL 2 6 0.3% 3.4% 5 0.3% 
OPHTHALMIC 1 20 1.0% 11.4% 14 0.8% 
OPHTHALMIC 2 5 0.2% 2.8% 5 0.3% 
OPHTHALMIC 3 2 0.1% 1.1% 2 0.1% 
LAXATIVE 1 65 3.2% 36.9% 60 3.3% 
LAXATIVE 2 36 1.8% 20.5% 22 1.2% 
LAXATIVE 3 9 0.4% 5.1% 5 0.3% 
OTC 1 39 1.9% 22.2% 19 1.0% 
OTC2 11 0.5% 6.3% 11 0.6% 
OTC 3 2 0.1% 1.1% 2 0.1% 
OTC 4 1 0.0% 0.6% 1 0.1% 
ANTIDIARRHEAL 5 0.2% 2.8% 4 0.2% 
SMOKING CESSATION AID 5 0.2% 2.8% 5 0.3% 
ANTI-COAGULATION AGENTS 53 2.6% 30.1% 51 2.8% 
OTHER 13 0.6% 7.4% 13 0.7% 
TOTAL 2024 100.0% 1150.0% 1821 100.0% 
AChIs; acetylcholinesterase inhibitors, CCB; calcium channel blocker, 5-ARIs s; 5α-reductase inhibitors, 
DPP-4Is; dipeptidyl peptidase 4 inhibitors, ACEI; angiotensin-converting enzyme inhibitors, ARBs; 
angiotensin II receptor blockers, PPI; proton-pump inhibitors, NSAIDs; nonsteroidal anti-inflammatory 
drugs, OTC; over the counter, SSRI; selective serotonin reuptake inhibitors, SNRI; serotonin and 
norepinephrine reuptake inhibitors 
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Number of 
medications 
per patient 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 0 2 1.1 1.1 1.1 
1 1 0.6 0.6 1.7 
2 4 2.2 2.2 3.9 
3 7 3.9 3.9 7.9 
4 10 5.6 5.6 13.5 
5 8 4.5 4.5 18.0 
6 10 5.6 5.6 23.6 
7 8 4.5 4.5 28.1 
8 15 8.4 8.4 36.5 
9 13 7.3 7.3 43.8 
10 14 7.9 7.9 51.7 
11 18 10.1 10.1 61.8 
12 9 5.1 5.1 66.9 
13 6 3.4 3.4 70.2 
14 9 5.1 5.1 75.3 
15 5 2.8 2.8 78.1 
16 3 1.7 1.7 79.8 
17 6 3.4 3.4 83.1 
18 9 5.1 5.1 88.2 
19 6 3.4 3.4 91.6 
20 4 2.2 2.2 93.8 
21 1 0.6 0.6 94.4 
22 3 1.7 1.7 96.1 
23 2 1.1 1.1 97.2 
24 3 1.7 1.7 98.9 
25 1 0.6 0.6 99.4 
27 1 0.6 0.6 100.0 
Total 178 100.0 100.0  
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Appendix F: Histogram Charts 
 
i Number of Medications 
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ii Number of Illnesses 
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Appendix G: Logistic Regression Outputs for “Enter Method” 
i Beers’ criteria 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases 
Included in Analysis 178 100.0 
Missing Cases 0 0 
Total 178 100.0 
Unselected Cases 0 0 
Total 178 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 All cases were included in the analysis. 
 
 The table above gives the coding for the 
outcome variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The table above shows how the values of the categorical variable ‘rank’ were handled. 
 
  
Dependent Variable Encoding 
Original Value Internal Value 
0 0 
1 1 
Categorical Variables Codings 
 Frequency Parameter coding 
(1) (2) (3) (4) (5) 
Age  
65-69 27 1.000 .000 .000 .000 .000 
70-74 31 .000 1.000 .000 .000 .000 
75-79 30 .000 .000 1.000 .000 .000 
80-84 35 .000 .000 .000 1.000 .000 
85-89 37 .000 .000 .000 .000 1.000 
90 and 
older 
18 .000 .000 .000 .000 .000 
Medications  
1 24 .000 .000 .000   
2 54 1.000 .000 .000   
3 47 .000 1.000 .000   
4 53 .000 .000 1.000   
Diseases 
1 42 .000 .000 .000   
2 39 1.000 .000 .000   
3 52 .000 1.000 .000   
4 45 .000 .000 1.000   
Gender  
FEMALE 93 .000     
MALE 85 1.000     
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Block 0: Beginning Block  
 
 
 
 
a. Constant is included in the model. 
b. The cut value is 0.500. 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant 0.529 0.155 11.614 1 0.001 1.697 
  
Classification Table
a,b
 
 
Observed 
Predicted 
Beers Percentage 
Correct 0 1 
Step 0 Beers 0 0 66 .0 
1 0 112 100.0 
Overall Percentage   62.9 
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  Variables not in the Equation 
Variables Score df Sig. 
Step 0 Male 0.611 1 0.434 
Overall age 
90 and older as reference 
12.694 5 0.026 
65-69 
0.757 1 0.384 
70-74 
2.044 1 0.153 
75-79 
0.775 1 0.379 
80-84 
0.000 1 0.993 
85-89 
0.240 1 0.624 
Overall number of medications 
(0-4 medications as reference) 
40.031 3 0.000 
5-9 medications 
2.823 1 0.093 
10-13 medications 0.041 1 0.840 
≥14 medications 28.212 1 0.000 
Overall number of illnesses 
(0-3 illnesses as reference) 
7.222 3 0.065 
4-5 illnesses 0.908 1 0.341 
6-8 illnesses 0.606 1 0.436 
≥9 illnesses 
4.121 1 0.042 
Cardiovascular disease 
0.466 1 0.495 
Neurological disease 
9.231 1 0.002 
Gastrointestinal disease 
0.631 1 0.427 
Respiratory disease 
6.173 1 0.013 
Musculoskeletal disease 
1.366 1 0.242 
Urogenital disease 
6.802 1 0.009 
Kidney disease 1.099 1 0.294 
Endocrine disease 0.894 1 0.344 
Cancer and immune system diseases 0.823 1 0.364 
Overall Statistics 58.259 21 0.000 
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Block 1: Method = Enter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 72.090 21 .000 
Block 72.090 21 .000 
Model 72.090 21 .000 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 6.126 8 0.633 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke 
R Square 
1 162.646
a
 0.333 0.455 
a. Estimation terminated at iteration number 6 because 
parameter estimates changed by less than 0.001. 
Contingency Table for Hosmer and Lemeshow Test 
 
beers = 0 beers = 1 
Total Observed Expected Observed Expected 
Step 1 1 17 15.856 1 2.144 18 
2 12 13.310 6 4.690 18 
3 12 11.467 7 7.533 19 
4 9 8.237 9 9.763 18 
5 3 6.464 15 11.536 18 
6 7 5.022 11 12.978 18 
7 4 3.262 14 14.738 18 
8 1 1.564 17 16.436 18 
9 1 .661 17 17.339 18 
10 0 .158 15 14.842 15 
 
Classification Table
a
 
 
Observed 
Predicted 
Beers Percentage 
Correct 0 1 
Step 1 beers 0 41 25 62.1 
1 16 96 85.7 
Overall Percentage   77.0 
a. The cut value is 0.500 
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Variables in the Equation   
 B S.E. Wald df Sig. Exp(B) 95% CI EXP(B) 
Step 1
a
 Male 0.204 0.449 0.206 1 0.650 1.226 0.508 2.959 
Overall age 
90 and older as reference 
 12.574 5 0.028    
65-69 
2.728 0.935 8.509 1 0.004 15.306 2.448 95.713 
70-74 2.812 0.892 9.928 1 0.002 16.638 2.894 95.648 
75-79 2.691 0.871 9.554 1 0.002 14.744 2.677 81.211 
80-84 1.634 0.808 4.090 1 0.043 5.124 1.052 24.963 
85-89 1.992 0.813 6.002 1 0.014 7.331 1.489 36.084 
Overall number of medications 
(0-4 medications as reference) 
 21.958 3 0.000    
5-9 medications 1.218 0.646 3.552 1 0.059 3.382 0.952 12.006 
10-13 medications 1.703 0.689 6.113 1 0.013 5.493 1.423 21.195 
≥14 medications 3.959 0.869 20.741 1 0.000 52.384 9.535 
287.78
5 
Overall number of illnesses 
(0-3 illnesses as reference) 
 0.954 3 0.812    
4-5 illnesses 
-0.533 0.644 0.683 1 0.408 0.587 0.166 2.075 
6-8 illnesses -0.465 0.710 0.430 1 0.512 0.628 0.156 2.524 
≥9 illnesses -0.805 0.914 0.776 1 0.378 0.447 0.074 2.682 
Cardiovascular disease 0.161 0.728 0.049 1 0.825 1.175 0.282 4.898 
Neurological disease 
0.937 0.517 3.278 1 0.070 2.552 0.926 7.034 
Gastrointestinal disease 
-0.689 0.499 1.909 1 0.167 0.502 0.189 1.334 
Respiratory  disease 
0.554 0.497 1.245 1 0.264 1.741 .657 4.610 
Musculoskeletal disease 
0.043 0.469 0.008 1 0.927 1.044 0.417 2.616 
Urogenital  disease 
1.645 0.732 5.051 1 0.025 5.180 1.234 21.740 
Kidney disease 
0.457 0.787 0.338 1 0.561 1.579 0.338 7.383 
Endocrine disease 
0.066 0.452 0.022 1 0.883 1.069 0.440 2.593 
Cancer and immune 
system diseases 0.562 0.531 1.120 1 0.290 1.753 0.620 4.960 
Constant -3.675 1.038 12.536 1 0.000 0.025   
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ii STOPP criteria 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases 
Included in Analysis 178 100.0 
Missing Cases 0 0 
Total 178 100.0 
Unselected Cases 0 0 
Total 178 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
 All cases were included in the analysis. 
 
 The table above gives the coding for the 
outcome variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The table above shows how the values of the categorical variable ‘rank’ were handled. 
  
Dependent Variable Encoding 
Original Value Internal Value 
0 0 
1 1 
Categorical Variables Codings 
 Frequency Parameter coding 
(1) (2) (3) (4) (5) 
Age 
65-69 27 1.000 .000 .000 .000 .000 
70-74 31 .000 1.000 .000 .000 .000 
75-79 30 .000 .000 1.000 .000 .000 
80-84 35 .000 .000 .000 1.000 .000 
85-89 37 .000 .000 .000 .000 1.000 
90 and 
older 
18 .000 .000 .000 .000 .000 
Medications 
1 24 .000 .000 .000   
2 54 1.000 .000 .000   
3 47 .000 1.000 .000   
4 53 .000 .000 1.000   
Diseases 
1 42 .000 .000 .000   
2 39 1.000 .000 .000   
3 52 .000 1.000 .000   
4 45 .000 .000 1.000   
Gender 
FEMALE 93 .000     
MALE 85 1.000     
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Block 0: Beginning Block 
Classification Table
a,b
 
 
Observed 
Predicted 
stopp Percentage 
Correct 0 1 
Step 0 STOPP 0 0 55 0 
1 0 123 100.0 
Overall Percentage   69.1 
a. Constant is included in the model. 
b. The cut value is 0.500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant 0.805 0.162 24.619 1 0.000 2.236 
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  Variables not in the Equation 
Variables Score df Sig. 
Step 0 Male 0.541 1 0.462 
Overall age 
90 and older as reference 
5.650 5 0.342 
65-69 0.369 1 0.544 
70-74 2.343 1 0.126 
75-79 0.014 1 0.907 
80-84 0.006 1 0.940 
85-89 0.393 1 0.531 
Overall number of medications 
(0-4 medications as reference) 
31.268 3 0.000 
5-9 medications 0.667 1 0.414 
10-13 medications 0.831 1 0.362 
≥14 medications 22.516 1 0.000 
Overall number of illnesses 
(0-3 illnesses as reference) 
7.934 3 0.047 
4-5 illnesses 0.000 1 0.984 
6-8 illnesses 1.197 1 0.274 
≥9 illnesses 2.124 1 0.145 
Cardiovascular disease 0.599 1 0.439 
Neurological disease 7.004 1 0.008 
Gastrointestinal disease 1.299 1 0.254 
Respiratory disease 8.281 1 0.004 
Musculoskeletal disease 5.737 1 0.017 
Urogenital disease 12.319 1 0.000 
Kidney disease 1.215 1 0.270 
Endocrine disease 0.112 1 0.738 
Cancer and immune system 
diseases 
1.349 1 0.245 
Overall Statistics 50.813 21 0.000 
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Block 1: Method = Enter 
 
 
 
 
 
 
 
 
 
 
 
 
Contingency Table for Hosmer and Lemeshow Test 
 
STOPP = 0 STOPP = 1 
Total Observed Expected Observed Expected 
Step 1 1 14 14.367 4 3.633 18 
2 13 11.300 5 6.700 18 
3 8 9.665 10 8.335 18 
4 5 7.265 13 10.735 18 
5 8 5.389 10 12.611 18 
6 4 3.539 14 14.461 18 
7 2 2.081 16 15.919 18 
8 0 0.897 18 17.103 18 
9 1 0.436 17 17.564 18 
10 0 0.061 16 15.939 16 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 65.489 21 0.000 
Block 65.489 21 0.000 
Model 65.489 21 0.000 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 6.175 8 0.628 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke 
R Square 
1 154.622
a
 0.308 0.434 
a. Estimation terminated at iteration number 6 because 
parameter estimates changed by less than 0.001. 
Classification Table
a
 
 
Observed 
Predicted 
stopp Percentage 
Correct 0 1 
Step 1 stopp 0 35 20 63.6 
1 17 106 86.2 
Overall Percentage   79.2 
a. The cut value is .500 
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Variables in the Equation 
 B S.E. Wald df Sig. 
Exp(B) 95% CI for EXP(B) 
Lower Upper 
Step 1
a
 Male 0.131 0.452 0.084 1 0.772 1.140 0.470 2.765 
Overall age 
90 and older as reference 
  7.646 5 0.177 
 
  
65-69 2.128 0.919 5.362 1 0.021 8.395 1.387 50.828 
70-74 2.184 0.885 6.084 1 0.014 8.881 1.566 50.365 
75-79 1.734 0.850 4.160 1 0.041 5.662 1.070 29.960 
80-84 
1.122 0.806 1.937 1 0.164 
3.071 
0.633 14.909 
85-89 
1.209 0.795 2.314 1 0.128 
3.352 
0.706 15.920 
Overall number of medications 
(0-4 medications as reference) 
 12.909 3 0.005 
 
  
5-9 medications 
0.723 0.601 1.445 1 0.229 
2.060 
0.634 6.691 
10-13 medications 
0.880 0.631 1.946 1 0.163 
2.412 
0.700 8.309 
≥14 medications 
3.078 0.871 12.487 1 0.000 
21.722 
3.939 119.788 
Overall number of illnesses 
(0-3illnesses as reference) 
 2.782 3 0.426 
 
  
4-5 illnesses 
.105 0.636 0.027 1 0.868 
1.111 
0.319 3.868 
6-8 illnesses 
-0.304 0.744 0.167 1 0.683 
0.738 
0.172 3.174 
≥9 illnesses -1.314 1.006 1.706 1 0.192 0.269 0.037 1.931 
Cardiovascular disease -0.013 0.719 0.000 1 0.985 0.987 0.241 4.036 
Neurological disease 1.104 0.554 3.974 1 0.046 3.016 1.019 8.928 
Gastrointestinal disease 
-0.242 0.514 0.221 1 0.638 
0.785 
0.287 2.152 
Respiratory disease 
0.897 0.561 2.554 1 0.110 
2.451 
0.816 7.360 
Musculoskeletal disease 
0.732 0.499 2.148 1 0.143 
2.079 
0.781 5.530 
Urogenital disease 
2.807 0.952 8.688 1 0.003 
16.554 
2.561 107.014 
Kidney disease 
1.192 0.918 1.686 1 0.194 
3.295 
0.545 19.931 
Endocrine disease 
-0.173 0.477 0.132 1 0.717 
0.841 
0.330 2.142 
Cancer and immune 
system diseases -0.556 0.519 1.144 1 0.285 
0.574 
0.207 1.588 
Constant -2.299 0.952 5.832 1 0.016 0.100   
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iii Combined criteria 
Case Processing Summary 
Unweighted Cases
a
 N Percent 
Selected Cases 
Included in Analysis 178 100.0 
Missing Cases 0 0 
Total 178 100.0 
Unselected Cases 0 0 
Total 178 100.0 
a. If weight is in effect, see classification table for the total number of cases. 
  All cases were included in the analysis. 
 
 The table above gives the coding for the 
outcome variable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The table above shows how the values of the categorical variable ‘rank’ were handled. 
  
Dependent Variable Encoding 
Original Value Internal Value 
0 0 
1 1 
Categorical Variables Codings 
 Frequency Parameter coding 
(1) (2) (3) (4) (5) 
Age 
65-69 27 1.000 .000 .000 .000 .000 
70-74 31 .000 1.000 .000 .000 .000 
75-79 30 .000 .000 1.000 .000 .000 
80-84 35 .000 .000 .000 1.000 .000 
85-89 37 .000 .000 .000 .000 1.000 
90 and 
older 
18 .000 .000 .000 .000 .000 
Medications 
1 24 .000 .000 .000   
2 54 1.000 .000 .000   
3 47 .000 1.000 .000   
4 53 .000 .000 1.000   
Diseases 
1 42 .000 .000 .000   
2 39 1.000 .000 .000   
3 52 .000 1.000 .000   
4 45 .000 .000 1.000   
Gender 
FEMALE 93 .000     
MALE 85 1.000     
 125 
  
Block 0: Beginning Block 
 
 
 
 
 
  Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant 0.996 0.169 34.800 1 000 2.708 
  
Classification Table
a,b
 
 
Observed 
Predicted 
beersstopp Percentage 
Correct 0 1 
Step 0 beersstopp 0 0 48 0 
1 0 130 100.0 
Overall Percentage   73.0 
a. Constant is included in the model. 
b. The cut value is 0.500 
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Variables not in the Equation 
Variables Score df Sig. 
Step 0 Male 1.758 1 0.185 
Overall age 
90 and older as reference 
5.757 5 0.331 
65-69 0.364 1 0.546 
70-74 2.239 1 0.135 
75-79 0.242 1 0.623 
80-84 0.057 1 0.811 
85-89 0.709 1 0.400 
Overall number of medications 
(0-4 medications as reference ) 
31.629 3 0.000 
5-9 medications 0.279 1 0.597 
10-13 medications 0.016 1 0.901 
≥14 medications 17.396 1 0.000 
Overall number of illnesses 
(0-3illnesses as reference) 
8.237 3 0.041 
4-5 illnesses 0.039 1 0.844 
6-8 illnesses 1.260 1 0.262 
≥9 illnesses 2.582 1 0.108 
Cardiovascular disease 0.412 1 0.521 
Neurological disease 7.119 1 0.008 
Gastrointestinal disease 2.814 1 0.093 
Respiratory disease 6.803 1 0.009 
Musculoskeletal disease 6.512 1 0.011 
Urogenital disease 9.486 1 0.002 
Kidney disease 0.603 1 0.438 
Endocrine disease 0.082 1 0.775 
Cancer and immune system 
diseases 
0.015 1 0.902 
Overall Statistics 47.228 21 0.001 
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Block 1: Method = Enter 
 
 
 
 
 
 
 
 
Contingency Table for Hosmer and Lemeshow Test 
 
beersstopp = 0 beersstopp = 1 
Total Observed Expected Observed Expected 
Step 1 1 16 13.503 2 4.497 18 
2 9 10.587 9 7.413 18 
3 5 7.709 13 10.291 18 
4 5 5.655 13 12.345 18 
5 6 4.336 12 13.664 18 
6 4 2.898 14 15.102 18 
7 1 1.756 17 16.244 18 
8 1 0.971 17 17.029 18 
9 1 0.477 17 17.523 18 
10 0 0.108 16 15.892 16 
 
 
 
 
 
 
 
 
 
 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 6.602 8 0.580 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 56.565 21 0.000 
Block 56.565 21 0.000 
Model 56.565 21 0.000 
Model Summary 
Step 
-2 Log 
likelihood 
Cox & Snell 
R Square 
Nagelkerke 
R Square 
1 150.956
a
 0.272 0.395 
a. Estimation terminated at iteration number 6 because 
parameter estimates changed by less than 0.001. 
 
Classification Table
a
 
 
Observed 
Predicted 
beersstopp Percentage 
Correct 0 1 
Step 1 beersstopp 0 27 21 56.3 
1 13 117 90.0 
Overall Percentage   80.9 
a. The cut value is 0.500 
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Variables in the Equation 
 B S.E. Wald df Sig. 
Exp(B) 95% CI EXP(B) 
Lower Upper 
Step 
1
a
 
Male 0.411 0.461 0.796 1 0.372 1.508 0.612 3.719 
Overall age 
90 and older as reference 
 
5.984 5 0.308 
 
  
65-69 1.736 0.910 3.638 1 0.056 5.674 0.953 33.771 
70-74 1.784 0.871 4.191 1 0.041 5.952 1.079 32.833 
75-79 1.490 0.835 3.184 1 0.074 4.438 0.864 22.807 
80-84 0.722 0.774 0.870 1 0.351 2.059 0.451 9.387 
85-89 0.855 0.762 1.260 1 0.262 2.352 0.528 10.477 
Overall # medications 
(0-4 medications as reference) 
 12.751 3 0.005 
 
  
5-9 medications 1.101 0.603 3.332 1 0.068 3.007 0.922 9.807 
10-13 medications 1.361 0.636 4.574 1 0.032 3.899 1.120 13.571 
≥ 14 medications 3.031 0.851 12.679 1 0.000 20.728 3.907 109.964 
Overall number of illnesses 
(0-3 illnesses as reference) 
 1.646 3 0.649 
 
  
4-5 illnesses -0.153 0.649 0.055 1 0.814 0.859 0.241 3.063 
6-8 illnesses -0.345 0.737 0.219 1 0.640 0.708 0.167 3.002 
≥9 illnesses -1.135 0.981 1.341 1 0.247 0.321 0.047 2.196 
Cardiovascular disease 0.036 0.744 0.002 1 0.961 1.037 0.241 4.455 
Neurological disease 1.031 0.577 3.192 1 0.074 2.804 0.905 8.690 
Gastrointestinal disease -0.002 0.519 0.000 1 0.997 0.998 0.361 2.758 
Respiratory disease 0.704 0.566 1.549 1 0.213 2.022 0.667 6.127 
Musculoskeletal disease 0.865 0.502 2.969 1 0.085 2.375 0.888 6.352 
Urogenital disease 2.273 0.936 5.894 1 0.015 9.712 1.550 60.870 
Kidney disease 0.507 0.869 0.340 1 0.560 1.660 0.302 9.119 
Endocrine disease -0.096 0.484 0.040 1 0.842 0.908 0.352 2.344 
Cancer and immune 
system diseases 
-0.074 0.536 0.019 1 0.890 
0.929 
0.325 2.657 
Constant -2.256 0.960 5.520 1 0.019 0.105   
